List of Biotech, Pharmaceutical & Life Sciences companies in California - 1797

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world's biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company's primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor).

3T is an immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. By leveraging the power of the immune system to recognize, target, and destroy cancer cells, 3T's technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Execute Relentlessly Join us in creating the future of genetic medicine.

High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics.

858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. 858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.

Aardvark Therapeutics is a clinical stage biopharmaceutical company focused on leveraging host adaptive responses through gut-brain signaling for the treatment of metabolic and inflammatory diseases. The company has multiple programs in its pipeline and has received FDA orphan drug designation for its novel drug candidate for Prader-Willi syndrome.

Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.

AAT Bioquest®, Inc. (formerly ABD Bioquest, Inc.) develops, manufactures and markets bioanalytical research reagents and kits to life sciences research, diagnostic R&D and drug discovery. We specialize in photometric detections including absorption (color), fluorescence and luminescence technologies. The Company's superior products enable life science researchers to better understand biochemistry, immunology, cell biology and molecular biology. AAT Bioquest offers a rapidly expanding list of enabling products. Besides the standard catalog products, we also offer custom services to meet the distinct needs of each customer. Our current services include custom synthesis of biological detection probes, custom development of biochemical, cell-based and diagnostic assays and custom high throughput screening of drug discovery targets. AAT Bioquest® is committed to constantly meet or exceed its customer’s requirements by providing consistently high quality products and services, and by encouraging continuous improvements in its long-term and daily operations. While we continue to rapidly expand, our core value remains the same: Innovation and Customer Satisfaction. We are committed to being the leading provider of novel biological detection solutions. We promise to extend these values to our customers during the course of our service and to continue to support our customers with new products and services.

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Abaxis develops and commercializes medical device and innovative technology and services that support best medical practices, enabling practitioners to respond to the health needs of their patients, while operating point of care, onsite diagnostics for human and animal health.Abaxis is now part of Zoetis.

As researchers are focusing their efforts on determining the biological functions, interactions and regulation of the human proteome, Abbiotec is dedicated to developing cell biology-based research tools that assist scientific discoveries. Besides custom services, Abbiotec offers over 12,000 antibodies, proteins, peptides, lysates and kits to assist researchers in understanding human biology and diseases at the cellular and molecular levels.

AbboMax is a biotechnology company that offers high quality, diagnostic-grade products and professional custom services for research purposes.

Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation. Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation. This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease. It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Abcentra is developing a potential solution for patients with cardiovascular inflammation – therapeutics that target oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease. Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline). Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors. Several additional indications are also being pursued. Abcentra has offices in Los Angeles. The Company’s ownership includes world-renowned Los Angeles hospital, Cedar-Sinai. Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.

Abeomics Inc. is founded by scientists for the scientists. Our immunologists, cell biologists and business professionals have contributed for over 25 years to the growth and success of global companies including BD Biosciences, eBioscience and IMGENEX Corporation. We bring our experiences to develop well-validated and specific antibodies by traditional hybridoma technology and by genetic engineering to produce recombinant mouse and rabbit monoclonal antibodies.

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

Abilita Therapeutics is a biotechnology company focused on redefining the druggable landscape for multi-span membrane proteins, including G Protein Coupled Receptors (GPCRs), transporters and ion channels. We are building a rich pipeline of high-value assets for such targets, with the goal of becoming the leader in discovering and developing first- and best-in-class antibody therapeutics.

Driven by a bold founding vision: Empowering patients from within, Abintus is pioneering potentially curative, off-the-shelf genetic medicines that engineer cells directly inside the patient’s body, also termed in vivo. These therapies are based on Abintus' clinically proven Modular Delivery Platform (MDP). The company’s two initial, fit-for-purpose, In Vivo programs are: 1. Highly selective gene expression targeting cell type/state via synthetic biology (e.g., In Vivo CAR-NK/T/Treg, In Vivo TCR-T) with applications across multiple gene delivery systems (e.g., AAV, lenti, adeno, retro) and therapeutic areas including leukemia, solid tumors, autoimmune, infectious, and genetic disease. 2. Simultaneous engineering of a diverse repertoire of active innate and adaptive immune cells (e.g., In Vivo CAR-X) with applications in diseases such as lymphoma and solid tumors. Abintus is leveraging over 20 years and $275 million of prior technology advancement for in vivo engineering including the treatment of over 350 patients through Phase 3 registration trials. Our company name comes from the Latin words “ab intus”, which means “from within”. We chose this name for 3 reasons: 1) Patients: We are pursuing product candidates that are designed to directly empower patients’ own immune cells to fight their disease from within. 2) Science: Our team is committed to scientific excellence and continual learning. Our differentiated technologies have the potential to directly reprogram activated immune cells “in situ”, or from within. 3) Culture: We believe our ability to achieve our vision will come from within - by building a performance-driven culture that prioritizes career development and rewards outstanding contributions. Abintus’ initial funding syndicate included Takeda Ventures and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP). Abintus Bio, Inc. (“Abintus”) is headquartered in San Diego. www.abintusbio.com.

Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities. The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties. Users of AlivaMab Mouse include the world’s largest pharmas, public and private biotechs, and leading academic institutions. AlivaMab Mouse-derived antibodies in clinical development span formats including IgG, multispecific, ADC, and CAR. Many partners use AlivaMab Mouse at Ablexis’ sister company, AlivaMab Biologics, a leading provider of services in antibody drug discovery, engineering, and protein sciences. Visit us at www.ablexis.com to learn more. For inquiries about licensing the AlivaMab Mouse, contact us at info@ablexis.com.

Ab Studio Inc. is a biotech company in the San Francisco Bay Area. We have extensive knowledge and expertise in the discovery, optimization, and development of therapeutic antibodies with complex designs, and combine conventional approaches with computer-aided antibody design in this process. Ab Studio believes in 'Quality by design' and aims to address current limitations in the field of therapeutic antibodies with novel technology platforms including multi-specific and internalization antibodies. Please visit our website for more details and partnership/service opportunities http://www.antibodystudio.com

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive partnership with Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and FTO. For over 20 years, AbTherx’s passionate, innovative, and collaborative team has pushed the boundaries of antibody discovery technologies, leading to over 1,000 successful antibody discovery campaigns and 13 marketed therapeutics. AbTherx’s industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes.

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company that develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is focused on developing therapies for a range of conditions.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

The company providesmolecular biology services includingproduction of antibodies, GPCRs, kinases, nuclear receptors, and many other classes of drug targets and therapeutic proteins

Accellix aims to enable cell and gene therapy companies to meet their key product QC requirements by providing fast and actionable multi-parameter results using the Accellix instrument and a room temperature stable cartridge. Accellix will continue to identify markets where its platform and assay migration expertise can be best combined to create meaningful opportunities.

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

Accuryn Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence. Currently, Accuryn Medical is developing a predictive health platform to help medical teams better predict adverse outcomes in critical care settings. The Accuryn® Monitoring System is not cleared for prediction of disease states or clinical conditions.

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson's, diabetes and cancer. Acelot's platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot's first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer's. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates. ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

ACON Laboratories is an international diagnostic and medical device company with our corporate headquarters in San Diego, California USA. For more than 15 years, ACON has led the way in making high quality diagnostic and medical devices more affordable to people all around the world. The ACON name is well known in over 130 countries. Headquartered in San Diego, California, the US office is the center of strategic management, administration, business development, innovative research and development. Our state of the art manufacturing facility is ISO 13485:2003 certified, FDA registered and has been inspected by US FDA. Our current product lines include Diabetes Care, Clinical Chemistry (including Urinalysis and Point of Care Tests) and Immunoassay EIA/ELISA. We also have a number of new products in the pipeline for introduction in the future.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Acutus Medical is a dynamic arrhythmia care company focused on developing distinct, innovative technologies that provide physicians and patients with improved results. AcQMap, AcQRef and AcQGuide devices are CE Marked and FDA cleared. Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease.

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

AddexBio is a global provider of quality services and products in basic research and development for the academia, pharmaceutical, and biotechnology industries. Our headquartered is based in San Diego, California, USA , we are in a solid position to provide quality services and products which are both cost-effective and time-efficient. Our products include biological and chemical research tools.

Aderans has developed artificial hair with artificial cuticles called "Cyber Hair" which in 2006, evolved into "Vital Hair." A wig made from this material can retain a natural texture after taking a bath or a dip in the pool and can be styled freely with a hair drier due to its natural texture and response to air, allowing for more styling options.

Preclinical biotechnology company leveraging proprietary structure-based technology to develop small molecule disaggregators and inhibitors targeting previously undruggable misfolded proteins in neurodegenerative diseases. Our pipeline consists of tau, TDP-43 and alpha-synuclein programs.

AdvanBio Inc., www.Advabio.com, a subsidiary of Autobio Diagnostics in the U.S is a fast-growing biotechnological company based in Irvine, CA. Established in 2021. We specialize in providing cutting-edge IVD Quality Control products & Reagents designed for a diverse range of analytes. In addition, we are committed to providing global partners with high-performance IVD Critical Raw Materials and services such as: • FDA Submission • Assay Development • Product Sales • New Technology/Biomarker Development We are committed to the advancement of medical laboratory technology and dedicated to the promotion of human health. We empower medical providers in making pivotal biomarker & diagnostic decisions with our portfolio of innovative technologies. #Advanbio#ADLM

Advanced Bifurcation Systems Inc. has developed a novel technology to enable effective stenting of coronary arteries at their branch points (bifurcations). This comprehensive platform is a paradigm shift in interventional cardiology that will reduce the need for open-heart surgery, hospitalizations, and repeat coronary angioplasties. The technology will simplify procedures and improve outcomes while reducing angioplasty times which results in significant improvement to the overall patient care at a reduced cost.

Scientists today rely on advances in computer science, applied mathematics, and computational science, as well as high-performance computing and networking facilities, to increase our understanding of ourselves, our planet, and our universe. The mission of Computing Sciences at Berkeley Lab is to achieve transformational, breakthrough impacts in scientific domains through the discovery and use of advanced computational methods and systems and to make those instruments accessible to the broad scientific community. The Computing Sciences organization advances computational science throughout the U.S. Department of Energy's Office of Science research programs. Our greatest strength is our people. They specialize in solving scientific problems using expertise in computer hardware and software, computational science, applied mathematics, networking, and middleware services. Computing Sciences carries out its mission by operating two national user facilities — NERSC and ESnet — and by conducting applied research and development in computer science, computational science, and applied mathematics, the three essential elements of computational modeling and simulation. Combining computer and network operations with research and development provides tangible benefits to both the scientists who use our systems and their research programs. Just as our R&D programs benefit science, the needs of scientists influence the direction of our research. These two sides of Computing Sciences'​ work — systems and services, and research and development — are more than complimentary. Each enhances the quality of the other. Computing Sciences is comprised of three divisions: the Computational Research Division (CRD), the National Energy Research Scientific Computing (NERSC) Center Division, and the Scientific Networking Division, which manages the Energy Sciences Network ESnet.

Advanced BioMatrix provides innovative 3D matrix products, transforming science to a new level of discovery. We extract and manufacture highly purified, native, extracellular matrix proteins for tissue engineering, 3D bioprinting, cell culture, drug discovery and any other application with cells. Visit us at www.advancedbiomatrix.com or our 3D bioprinting page at www.bioprintabm.com

AB is proud to be the only U.S. based manufacturer of cochlear implants and equally proud to be a part of the larger Sonova group. At AB, success begins with a passion for hearing restoration and is driven by our global workforce of over a thousand employees. For more than 25 years, AB has removed limitations for those otherwise isolated from the world of sound. Always focused on bringing meaningful change through innovative technology, AB has set the standard for performance, lifestyle support, and access to sound in the field of cochlear implantation. Having implanted over 100,000 ears in over 130 countries and established a track record for developing high-performing, state-of-the-art products, our team of talented scientists, engineers, audiologists and other professionals are driven to succeed, work with integrity, and stay firmly committed to quality. Sonova companies include brands focused on hearing aids, cochlear implants, wireless communications, and clinical service. Together, we strive to create a world where everyone enjoys the delight of hearing and lives a life without limitations.Advanced Bionics is a global leader providing solutions for severe-to-profound hearing loss.

Over the past decade, Advanced Brain Monitoring has developed and implemented mobile, user-friendly platforms for acquiring, integrating, analyzing and reporting multi-sensor data in real-world applications. Our strong and growing technical team includes PhD- and masters-level hardware engineers, biostatisticians, software engineers and experts in signal processing, experimental design and clinical trials. ABM seeks to build on existing collaborations within the academic community and develop strategic partnerships across industry with like-minded professionals.

With a complete platform of core trauma and extremity products, AOS has become a trusted leader with its entire focus on the orthopaedic trauma industry. Relying on the professional guidance of the four original founding partners, as well as the clinical expertise and training of skilled surgeon champions, AOS designs and manufactures innovative orthopaedic trauma products with intra-operative and postoperative clinical benefits. AOS’s products are distributed worldwide through independent distributors and agents. By continuing to build strong relationships with our valued distribution network and surgeon users, AOS continues to improve every aspect of the way we do business. Especially for our patients and their families worldwide.

Serving the SynBio materials, foods and pharma industries with comprehensive facilities/equipment service programs, We help customers optimize their processes with the most cost effective systems, services, and processes to keep them running on schedule and in budget. Facilities/Equipment Performance Management Service Contracts Upstream Process Consulting - Bioreactor specification - Sensors, Sampling solutions - Automation - Integration Downstream Process Consulting - Filtration - Chromatography - Separations - Drying Calibration – instruments measuring -Temperature - Pressure - Flow - Mass - Optical - Volumetric - Dimensional NIST traceable "cradle to grave" calibration - Performance - Logging - SOP's - Records management Validation – IOQ generation, execution and reports OEM Post Sale Services Management - Installation - Calibration - Integration - On-site Services - Mail-in or Remote Service Center repairs - Warranty Record and Services Management Laboratory/Plant - automation, integration and maintenance Labor Services - field and contract service Equipment Sales - OEM supporting services in process design and performance service contracts - OEM Services Partners include;; Sonotec Non-invasive Flow Meters, BlueSens offgas Analyzers, APS Corp. Industrial Bioprocess Systems, Chemglass Labware, Hamilton Instruments, SecureCell Laboratory Automation

Advenchen is a pharmaceutical company that focuses on small molecule cancer drug discovery programs with a specialization in protein kinase inhibitors.

Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Advin Biotech is a FDA Registered growing corporation and manufacturer specializing in rapid diagnostics products for drugs of abuse testing with China and US based manufacturing facilities. Offering a complete line of one step drug tests for medical workplace and criminal justice professionals. Advin's 501k cleared products are intended for OTC, CLIA and professional use in cup, dip-card and cassette test formats. With full R&D and manufacturing capabilities located in our San Diego, California plant we are positioned to respond to the needs of partners and customers worldwide. We have the intra-company organic chemistry expertise to facilitate the design and synthesis of immunogens and the complementing ability to use the resulting immunogens to generate antibodies for the sensitive and specific detection of antigens and biomarkers. We encourage partnerships and co-development opportunities accordingly. Our short-term strategic goal is to augment our existing FDA cleared test menu with first-to-market, "organically-grown" assays targeted to fill the many gaps in the diverse toxicology market. Our long-term goal is to foster partnerships in the worldwide medical and forensic communities with a shared goal of providing affordable, accurate and actionable tests that fill unmet needs.

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. This therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payors and physicians. The company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory and commercial success.

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS penetrant selective mTORC1 inhibitor being developed for the treatment of TSC refractory epilepsy and is currently being evaluated in a Phase 1 trial. TSC is a rare genetic disorder caused by the hyperactive signaling of mTORC1. Beyond AV078, we've developed a proprietary library of small molecules, which are potent and selective mTORC1 and CD38 inhibitors that have the potential to precisely target the underlying biology of multiple rare and age-related disease

Aequor -- pronounced Acorn without the "n" -- means "The Sea" in Latin. Aequor's Founder discovered new chemicals in the ocean that are more potent and less toxic than anything known to kill bacteria and fungi -- including the antimicrobial resistant (AMR) Superbugs. PRODUCTS: Our platform includes "green" chemicals and products containing them for B2B sales and licensing: --Available now: 25 specialty chemicals - EPA/TSCA-approved --ingredients for consumer products to replace harmful biocides --proprietary formulations - sprays, washes, paints, coatings, etc.: --treatments for improving algae and yeast biomass production processes up to 40% in half the time for biofuels and renewable co-products --surface cleaners --water treatments --Pending EPA/FIFRA approval: 30 antimicrobials that are "green" and non-toxic for products and treatments making antibacterial, antifungal, antibiofilm and antifouling claims --Pending FDA approval : 30 new drug candidates The NIH offered Aequor free pre-clinical trials for 4 of the new drug candidates if we can deliver to them half-kilo samples. The DOD offered the same for up to 5 new drug candidates. SERVICES Aequor offers microbial and biofilm testing services for third parties seeking to determine efficacy of their formulations, devices, etc. UNMATCHED EXPERTISE Aequor's Founder Cynthia Burzell, Ph.D. - Marine and Medical Microbiology -- is considered a pioneer in Biofilms. She lectures internationally and offers educational training programs on biofilm and its impacts on the costs and operational inefficiencies in agro-industry, consumer, and healthcare sectors. UNMATCHED MODEL Aequor is a resident company at JLabs San Diego, raised $1.2M cash and is a Woman Owned Small Business, eligible for 5% of government contracts. For our in-house and virtual management team and updates, see our website. For further information: Marilyn Bruno , CEO - mbruno@aequorinc.com

Aether's mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

AfaSci, Inc., a San Francisco Bay Area biotech company committed to enhancing health care by conducting R&D in both Biotechnology and Therapeutics. Our bioengineering team has designed, produced and been marketing an in vivo drug screening platform, SmartCageTM. This system enables automated, and objective assessment of drug effects on rodent behavior and increases throughput of phenotyping of transgenic animals. Elevating our proprietary platform and well-established electrophysiological techniques, AfaSci’s scientists have been discovering IND drug candidates targeting ion channels and GPCR for the treatment of CNS disorders, especially neuropathic pain, epilepsy and Alzheimer’s disease.

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Agastiya Biotech merges advanced, Eastern knowledge with rigorous Western R&D in order to deliver breakthrough innovative pharmaceuticals to the marketplace. Over 40% of all pharmaceutical drugs, including sophisticated chemotherapy and anti-viral drugs, are derived from natural plant sources. Through investigation of ancient Eastern botanical knowledge combined with high throughput and AI driven analysis, Agastiya Biotech engineers best in class novel small molecules for treatment of disease. We are leading the discovery and design of ground-breaking small molecules to revolutionize medicine and find a cure for the diseases of our time.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Genuity was an early ISP (Internet Service Provider) focusing on commercial customers. It was among the pioneers to offer data center services at facilities with high Internet capacity. It was acquired by GTE/BBN. The company was made independent through the process of consolidating various companies to what is today Verizon.

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company's third-generation AI system delivers lightning-fast virtual screening and multi-objective pharmacological profile optimization for small-molecule, antibody, and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a shortlist of candidates with a very high wet-lab hit rate, and a dramatically reduced discovery time and cost. To learn more, visit ainnocence.com.

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

AIVITA Biomedical is an Irvine, CA based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development. These proprietary capabilities enable us to turn therapeutic discovery into reality, developing revolutionary cell-based treatments and healthcare products for the patients who need them. AIVITA is developing treatments for cancer, vision loss, and is bringing next-generation skincare formulations to consumers through its commercial product offerings.

AiViva BioPharma, Inc. is a privately owned clinical stage biotech developing novel technologies to address unmet medical needs by transforming existing treatments to create localized, targeted treatment of diseases while limiting systemic exposure. Our core competency includes development of drugs using our proprietary JEL™ Technology in specialty therapeutic areas of Dermatology, Ophthalmology, Urology, and Oncology.

We are creating a new category of medicines with the application of spatial biology and AI.

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Alcala Labs was founded by a partnership between a healthcare attorney specializing in the defense of individual and institutional healthcare providers and a physician with one of the largest pain management practices in Southern California. The lab grew out of frustration with existing laboratory providers and the conviction that Alcala Labs could do better. Smaller labs were not scientifically up to the task and, in many cases, were simply dishonest about the services they provided. Larger labs were either unresponsive or subcontracted critical complex lab services to unaccountable third-party labs . Alcala Labs was built to react quickly to the needs of physicians who need to understand drug use and efficacy in their practices. The Alcala difference is accessibility to its physician customers, responsiveness to their needs and inquiries, and customizable lab testing. If a physician has a medical-legal question that arises from testing, he can immediately reach the company's healthcare attorney President. If a physician requires insight into how a particular test affects the course of a patient's care, she can engage in a dialogue directly with the lab's Medical Director. If there are questions about science and the development of new tests, our highly credentialed scientific team can be reached directly. Widely in demand among a variety of specialties, Alcala Labs is of especial importance to drug rehabilitation, pain management, and psychiatry practices. We're able to add assays as illicit "designer" drugs begin to appear, and our new pharmacogenetic department gives physicians the power to anticipate the right drugs and dosages to best treat their patients. Located in San Diego, Alcala is a laboratory of national reach and reputation. It is among the fastest growing labs in the country, dedicated to state-of-the-art science and the highest quality service.

We build and operate in-house pharmacies for safety net clinics, with a focus on STD clinics, Ryan Whites, and FQHCs serving patients living with HIV and Hepatitis C. We provide the entire physical, clinical, and digital infrastructure needed to operate and grow best-in-class 340B pharmacy programs. Our team has deep clinical pharmacy, technology, and operations experience. Together, we have spent 18 years in Africa building the largest HIV access program in the world, and we have set up, operated and scaled pharmacies that have dispensed over 25M+ prescriptions to patients across all 50 states in the US. After setting up your in-house pharmacy, we design and implement clinical pharmacy programs and deploy technology products that leverage your pharmacy to expand patient reach, improve clinical outcomes, and increase the financial impact of your 340B program. We are on a mission to serve safety net clinics and their patients. Drop us a line at hello@alchemyhealth.com.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alere is now Abbott! Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.

Alessa Therapeutics is a biotechnology company that specializes in developing localized treatments for solid organ disease.

Algae-C is developing a platform for the sustainable and low cost production of plant-based ingredients. The companycreates designer microalgae that produce valuable ingredients for the pharmaceutical, nutraceutical and therapeutics industries.

Algen Biotechnologies is a biotechnology company that specializes in revolutionizing therapeutic drug discovery through advanced CRISPR gene-modulation and AI.

Our scientists redesigned plastic materials to harmonize with nature. Our patented Soleic® technology is the world’s first high performance, renewable, and fully biodegradable plastic material made from algae. Algenesis was founded in 2016 by three professors from UC San Diego, Dr. Stephen Mayfield, Dr. Micheal Burkart, and Dr. Robert Pomeroy. Together they combined their knowledge and background and worked their way into the polymer market where customers had an unmet sustainability need. Traditional petroleum plastics are responsible for a tidal wave of air, land, and sea pollution that is destroying ecosystems and harming wildlife. Soleic® technology was developed to address this global plastic pollution crisis. Our initial product line consists of soft foams for footwear and hard foams for surfboards. We continue to research new applications for Soleic® technology. Algenesis is also developing new technologies with exciting product applications across multiple industries

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

Building a modern operating system for IVF, powered by artificial intelligence.

Aligen is a Pharmaceutical, Nutraceutical, and Cosmetic manufacturer that specializes in Softgels, Capsules, Tablets, Gummies, and Skincare Topical Creams.

We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com

Our strategy is to develop pharmacologically optimized drug candidates, which are first assessed in healthy volunteers and patients as monotherapy prior to their use in combination regimens designed to achieve improved treatment outcomes in patients. Our initial areas of focus are viral and liver diseases where our team can leverage their in-depth knowledge and expertise to develop potentially best-in-class combination regimens for each disease area with significant unmet medical need.

AlivaMab Biologics is a biotechnology company based in San Diego, California, focused on therapeutic antibody discovery and development. The company provides integrated solutions to accelerate the creation of biologics, delivering fully human antibodies with a commitment to speed and reduced development risks. Their mission is to create efficient pathways for partners in the pharmaceutical and biotechnology sectors. The team at AlivaMab includes experienced professionals from leading global pharmaceutical companies, contributing to over 500 discovery programs and 35 clinical candidates. They utilize advanced technologies, such as the AlivaMab® Mouse platform, to generate high-quality antibodies and offer a range of services, including antibody engineering and target validation. AlivaMab collaborates with numerous top-tier pharmaceutical companies, with several of their antibodies currently in clinical trials.

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

They are focused on the discovery and development of novel biotherapeutics to combat the debilitating muscle and bone loss and the loss of functional capacity, as occurs in various neuromuscular diseases, cancer cachexia, congestive heart failure, geriatric sarcopenia and frailty, as well as in other chronic diseases, for which no approved therapies are currently available.

Alixia is a medical research company that engages in developing new modalities to treat cancer, aging, and inflammation.

Alkahest, a subsidiary of Grifols, is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation. The company’s breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer’s disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Alkahest is based in San Carlos, Calif., while Grifols, a global healthcare company, is headquartered in Barcelona, Spain.

Alladapt was co-founded in 2018 in Palo Alto, California, by allergist and protein biochemist Kari Nadeau, MD, PhD, and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure, under tightly controlled clinical supervision, to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens.

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.

AllCells is a biotechnology company that specializes in high-quality human primary cells and hematologic tissue products. Founded in 1998, it has become a leader in blood donor cell collections and supports drug discovery, development, and manufacturing of cell therapies. In July 2022, AllCells was acquired by Discovery Life Sciences, which enhanced its capabilities through access to a larger biospecimen inventory and multi-omic biomarker services. The company offers a variety of services to support cell and gene therapy programs. These include donor management services to help clients find ideal research donors, as well as support for both prospective and retrospective clinical studies. AllCells also provides multi-omic analytical solutions for characterizing biospecimens and CGT products. Its product portfolio features blood and marrow-derived products, autoimmune diseased cells and tissue products, and hyper-annotated biospecimens, all essential for biomedical applications.

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. Our knowledgeable scientists and technicians are available to answer questions regarding any of our products. Over the past decade, Allele has become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services.

Harvesting the power of Nature, Allied Microbiota develops advanced microbes to clean-up environmental contamination faster, more sustainably, and more cost-effectively than traditional remediation methods. Our products tackle the toughest contaminants like those from manufactured gas plants, chlorinated organics, and even emerging contaminants like per- and poly-fluoroalkyl substances (PFAS). We developed a heat-loving microbe called ThermO+ that breaks down contaminants at a fraction of the cost and significantly faster than traditional methods. Powered by heat and on oxygen, our microbes can clean difficult contaminants such as chlorinated compounds like polychlorinated biphenyls (PCBs), petroleum products, and dioxins from the soil, turning brownfields into greenfields. We don't bury the problem. We solve it. Site cleans ups can be expensive, but our technology makes this possible for companies, developers, and communities. We aim and strive to create cleaner, healthier, and productive areas around the world. Make Allied Microbiota your fast, affordable, and go-to solution for a cleaner tomorrow.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

Allvivo Vascular is a medical device company that develops biomimetic coatings for devices, offering dual function coatings with nonthrombogenic and antibacterial properties.

Alphalyse has pioneered the use of mass spectrometry analysis since 2002. Our scientists have completed over 5,000 protein characterization analyses, including forced degradation studies and over 400 LC-MS-based residual/host cell protein projects. Currently, we are the only CRO in the World certified to offer LC-MS-based MRM analysis under GMP for release testing. As a specialist contract research organization (CRO), we offer protein analysis services to support biopharmaceutical companies in developing and manufacturing patient-safe products such as mAbs, vaccines, recombinant proteins, and cell & gene therapies. You can count on us to work closely with you on developing well-characterized biologics by challenging and improving analysis methods using top-of-the-line mass spectrometry technology (LC-MS). Our comprehensive reports will allow you to carry out data-driven process development and regulatory documentation under ICH Q6B guidelines. Our services include analytical characterization of biopharmaceuticals, mass spectrometric peptide mapping, host cell protein analysis, and quantifying specific proteins in complex samples.

Alpha Medical Instruments,developer, manufacturer, Balloon flotation catheters, venous catherization, right heart, measurements, venous, pulmonary artery pressures, cardiac output

ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through innovation. ATEC’s Organic Innovation Machine™ is the greatest concentration of spine knowhow in the industry and committed to the creation of clinical distinction. Leveraging 100% spine focus and expertise, we seek to improve spine surgery by rethinking, redesigning and seamlessly integrating the technologies required from the ground up. The innovation that results from that process is being rapidly adopted because, like us, spine surgeons covet informatic and procedural sophistication that enables more predictable, more reproducible care. Our flagship technology, the Prone TransPsoas (PTPTM) Procedure, leveraged decades of experience to advance first-generation lateral surgery with a more familiar patient position and elevated neuromonitoring.   EOS imaging, the backbone of ATEC’s informatic ecosystem, provides radiographic imaging, enabling standing, full-body, global alignment assessments. We are further developing EOS technology to elevate spine care with unprecedented capabilities. Our vision is to be the standard bearer in spine. Visit our website for more information: www.atecspine.com

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

ALSTEM is an early stage biotech company based in the San Francisco Bay Area specializing in Induced pluripotent stem cells and reprogramming technologies. Founded in early 2012 by a team of scientists with deep experience in both academic and industrial biotechnology, ALSTEM is advancing frontiers in genome editing, virus packaging, cell immortalization, and iPS cell technology.

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

AltiBio, Inc. is a San Francisco Bay Area biopharmaceutical company founded in early 2017 to bring relief to people living with rare and severe diseases. The management team has extensive experience developing and commercializing orphan therapeutics. The company currently has three projects in development, with two molecules. More news will soon be coming as the company nears its next big milestone...

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

Altos Labs is a biotechnology company focused on restoring cell health and resilience through cell rejuvenation to reverse disease, injury, and the disabilities that can occur throughout life. The company comprises a community of leading scientists, clinicians, and leaders from academia and industry working together towards this common mission. Altos operates in the San Francisco Bay Area, San Diego and Cambridge, UK. Note: Altos Labs will not ask you to download a messaging app for an interview or spend your own money to get started as an employee. If this sounds like your interaction with people claiming to be with Altos, it is not legitimate or a practice within our organization.

AltruBio is developing first-in-class immunomodulators to target diseases of the immune system. Our world-class global team brings a breadth of expertise in immunology and drug development to bring our biologic treatments to patients.

The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can help us move surgery into the light.

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Aluna is designed to help you understand your chronic respiratory condition (such as asthma) and allow you to take control of your lung health. Using a combination of machine learning, our spirometer device and mobile app, you can now use the daily measurements to help you understand and manage your asthma.

At Alveo, we're on a mission to use our open, accessible, and actionable molecular detection platform to detect pathogens before they spread. Our portable, handheld, analyzer and cloud-based data analytics brings molecular detection out of the lab and into the field. Alveo's agile platform can be adapted to detect a wide range pathogens including viruses, bacteria, and fungi. Whether testing a patient at a pharmacy at the point-of-care, chickens pen-side at the point-of-need, or farmers testing crops in-the-field, Alveo's technology brings users real time data precisely when and where it matters most. Partner with Alveo today to bring the power of early detection to your industry. Know Sooner, Act Faster™.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.

Current methods for disposal and reuse of waste polymer materials areinefficient, low-value, and altogether broken. We believe that breakthrough science and engineering can deliver more efficient reuse of these materials.Ambercycle is developing chemical technology to produce conventional polymers, such as polyesters,from a variety of fibrous waste streams. Student startup out of UC Davis

Focusing on generating innovative biological respondents with a unique mode of action coupled with conditionally activated characteristics, we handle high-value disease targets with huge upside potential, which are otherwise intractable for traditional targeting approaches.

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California.

Ambry Genetics is a company built by scientists, genetic counselors and physicians, dedicated to leading the clinical genomic diagnostic industry. Ambry boasts the largest genetic sequencing lab in the world; is CAP-accredited, CLIA-licensed and, as part of the Konica Minolta family, has access to the most complete suite of diagnostic technology in the world. Ambry Genetics'​ scope of clients includes some of the world's most respected academic institutions, pharmaceutical companies and leading treatment hospitals. Our experience, technology and dedication to science make us a trusted source for all clinical genetic testing, and an ideal partner for developing precision medicine solutions. Patients are at the core of everything we do, which is why Ambry partners with several non-profit organizations so that we can help both patients and clinicians alike find answers. Hiring Fraud Alert: Ambry/REALM IDx has received reports of employment scams in recent months that seek financial commitments, or requests personal information from job candidates. Unsuspecting job seekers have reported receiving unsolicited contacts by phone, email or text from individual(s) posing to be or represent Ambry/REALM IDx recruiter(s). If you've experienced either of these scenarios, please visit this page to learn more about hiring fraud: https://consumer.ftc.gov/articles/job-scams. Or visit https://realmidx.com/careers/recruitment-fraud-alert/ to learn more about our policy on recruitment fraud. You can confirm the legitimacy of a job posting by viewing our current open roles at https://realmidx.com/careers/.

ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer's disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer's disease, but other Neurodegenerative Conditions such as Huntington's disease, Parkinson's disease and MS, and recover quality of life for those patients and their families.

American River College offers a wide variety of degree and certificate programs in general education, transfer, and career education areas. We will work with you to help you identify your career goals and a custom educational path. We are proud to serve the diverse communities of the greater Sacramento region. In addition to our main campus on College Oak Drive, American River College also serves students at our Natomas, McClellan, and Mather centers. These educational centers give you access to quality higher education close to home and work, where you can take advantage of a variety of course offerings and support services to help you succeed. American River College strives to uphold the dignity and humanity of every student and employee. We are committed to equity and social justice through equity-minded education, transformative leadership, and community engagement. We believe this commitment is essential to achieving our mission and enhancing our community. We understand you may have job and family obligations that can make attending college a challenge. That's why we offer flexible scheduling options to meet your needs, including full-term and short-term classes, evening and weekend options, and classes that are fully and partially online.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amicrobe is a biotechnology company that develops locally applied products using the Amicidins™ technology platform for preventing and treating life-threatening infections with reduced commercial risk.

AmMax is a private biotechnology company focused on the clinical development of innovative cancer therapeutics. The Company strategically acquires oncology assets to develop into innovative and clinically meaningful products. It leverages its expertise in translational science to pursues first-in-class or best-in-class therapeutics with significant market opportunity. The company is focused on leveraging its CSF1R mAb platform licensed from Amgen, to launch multiple oncology products that address colorectal cancer with minimal residual disease (CRC MRD), tenosynovial giant cell tumors (TGCT), and an antibody-drug-conjugate construction for acute myeloid leukemia (AML) and solid tumors. AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc., which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization. With a seasoned management team, a versatile technology platform and a robust pipeline, AmMax is poised to grow into a leading biotech company. For more on AmMax Bio and its pipeline, please visit the Company’s website at: www.AmMaxBio.com.

Amphastar Pharmaceuticals is a recognized pharmaceutical company that uses state-of-the-art, cGMP-compliant facilities to develop, manufacture, and market biopharmaceutical injectable, intranasal, and inhalation products. In addition to the Corporate Headquarters, Amphastar has five manufacturing facilities in the United States, China, and Europe, along with a state-of-the-art New Drug Research Center. As a commitment to high quality, all Amphastar finished products are manufactured in the United States.

Amprion pioneers Testing for diseases associated with mis-folded proteins. Our flagship product - SYNTap is the assay used by the Michael J Fox Foundations Parkinson's Progression and Markers Initiative (PPMI) to define PD and DLB and its stages. Early diagnosis of synucleinopathies can help guide management, treatment and prognostic discussions. https://www.ampriondx.com

Amron International is a manufacturing company that specializes in high-quality diving, tactical, hyperbaric, and outdoor equipment with over 30 years of industry experience.

Established in 1993 in California, USA, Amsino is a leading medical device developer and manufacturer dedicated to advancing healthcare worldwide by developing, manufacturing, and marketing medical products that help improve the safety and effectiveness of patient care. The Amsino product portfolio includes Sterile Water and Saline, IV Therapy, Waste Fluid Management, Respiratory, Urology, and Enteral Feeding products. Amsino products are distributed in the United States and more than 80 countries worldwide. Visit www.amsino.com for our complete product offering.

In neuroscience, where so much is yet to be explored, it’s crucial that scientists and researchers can devote their time to discovery. Through a partnership with a team of experts at Amuza, researchers gain access to precise tools that get data right the first time and opens the door to discovery. Amuza is a researcher-focused company. We provide instruments and support to improve productivity and outcomes for life science research and the quality of human life.

Amygdala Neurosciences is a biopharmaceutical company whose mission is to invent and develop first-in-class medicines to treat substance use disorders (SUD). Amygdala Neurosciences, headquartered in San Francisco, CA, is an independent small biopharmaceutical company founded in 2015.

AmyriAD Therapeutics is a privately held, late clinical-stage pharmaceutical development company focused on advancing effective therapies for Alzheimer's Disease (AD). The company's leadership has a legacy of success in AD drug development and brings together decades of experience in AD with the singular goal of developing innovative treatments for this debilitating condition.

Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

CenExel ACT is dedicated to performing medical clinical trials to find new patient therapies in unique areas, including Japanese-and Chinese-bridging studies. Our Phase I Clinical Pharmacology Unit is a 30,000 SF, state-of-the-art, 90 beds, clinical research center, and features: Private patient rooms and ward setting, State of the art entertainment 24-hour medical coverage, 7 days a week, On-site Surgery Suite (2 Procedure Rooms, 3 Recovery Beds), Emergency Room and Intensive Care Unit located close by In the clinical trials area, we ffer investigational therapies for indications such as Migraines, Insomnia, Chronic Pain, Osteoporosis, Hormone Replacement Therapy, Diabetes and much more. We offer new and existing therapies that manage conditions where other medical therapies may have failed. Each and every CenExel patients receive the highest quality medical care. We notify the patient's primary care physician of enrollment and ongoing status and provide a full report at the conclusion of each study. To learn more about working with us as a Sponsor or CRO for your clinical trial visit CenExel.com/ACT or call 714-774-7777.

AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.

AnaSpec, a subsidiary of Kaneka Eurogentec, is a globally recognized biotechnology company that manufactures and sells custom and catalog Peptides, Fluorogenic and FRET Assay Kits, Fluorescent Dyes, Amino Acids and more, for research use, drug discovery and diagnostic use. We also manufacture custom Peptide based starting materials for GMP applications. As a trusted and long-standing provider to the biopharmaceutical and diagnostic industries, academia, and governmental institutions, we aim to empower the scientific community in their endeavors to elucidate diseases and enhance health and well-being, through our quality proteomic products and services. Our team of experts strive for excellence with honesty and transparency on behalf of our customers. AnaSpec established in 1993 is certified to ISO 9001:2015.

Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds our clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds our preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds our preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and we anticipate to select a clinical lead for CHB by mid-2022. Certain former executives and former shareholders of Teneobio, including Lightspeed Venture Partners and Sutter Hill Ventures, have formed Ancora Biotech to oversee all manufacturing and clinical development of these assets.

ANEUVO® is a Platform and Therapy Development company focused on treating chronic injuries and conditions that have not been curable through traditional pharmaceutical approaches. ExaStim™ is a non-invasive neuromodulation system developed by Aneuvo that has received FDA Breakthrough Device Designation for treating spinal cord injury.

At Angarus, we are developing a new class of therapeutics that selectively targets immune-activating and immunosuppressive pathways within the tumor microenvironment, using predictive biomarkers for a more powerful, precise, and coordinated attack against cancer.

Angeles Therapeutics is a next generation cell and immune therapy company based on the technology licensed from the laboratory of its founder @PreetChaudhary. Angeles has developed a novel CAR-T and CAR-NK platforms that provide physiological TCR signaling and overcomes most of the limitations of current generation CAR-T. Most importantly, our platform is highly effective against solid tumors. Angeles has also developed one of the largest portfolio of CAR-T and CAR-NK in the world targeting more than 130 antigens covering cancer, infection and immune disorders. Our platform is fully compatible with autologous, allogeneic, universal and bispecific approaches. Angeles has recently entered a partnership with a global major pharmaceutical company and is looking for additional partnership opportunities for further development of its portfolio.

Angiocrine Bioscience is a private, clinical stage engineered cell therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions. Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncologic and immunologic conditions, as well as, regenerating tissues and organs that have been injured or damaged by diseases.

Since 2016, AnimalBiome has helped tens of thousands of pet parents and veterinarians monitor and improve the gut health, and overall health, of companion animals around the world. See how we can help your pet or veterinary practice at animalbiome.com or animalbiome.vet (veterinarians only).

Animal Cell Therapies engages in research and development of stem cell treatments for orthopedic and chronic diseases in dogs.

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics. Anivive. Smarter for pet health.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Annam Biosciences is a biotechnology company that focuses on developing transformative drug delivery technologies and drug candidates.

Annexon Biosciences is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative diseases, including ophthalmic diseases.

Anresco offers a full range of microbiological services including routine QA testing, FDA Detention Without Physical Examination (DWPE) testing, shelf life studies, inoculation challenge studies, validations of food safety programs (e.g. for compliance with HACCP), and FSMA mandated environmental testing. With decades of experience working with manufacturers, importers, product developers, and more, their microbiologists have the professional expertise to help ensure the safe consumption of all perishable food products.

At Ansa Biotechnologies, we’re developing a way to synthesize DNA that will accelerate innovation in medicine, agriculture, and industrial biotechnology. Our fast, clean, and accurate enzymatic DNA synthesis process can produce gene-length molecules directly, overcoming bottlenecks of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world's biggest problems in health and sustainability. Note that Ansa does not conduct any employment discussions via LinkedIn. All official Ansa career openings are exclusively listed on our website careers page.

Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics. Our lead product, DAS181, is a multi-function sialidase fusion protein for host-cellprotection in respiratory virus infection, including parainfluenza, influenza and COVID19,. We are also advancing several additional programs in oncology and autoimmune diseases using our sialidase platform technology.

Antech Diagnostics, Inc., operates a network of veterinary diagnostic laboratories in the United States. It offers veterinary diagnostics services in the areas of chemistry, hematology and coagulation, endocrinology, serology and immunology, urine and fecal, therapeutic drugs, cytology and histology, and microbiology. The company provides laboratory medicine to veterinarians, as well as provides daily services to animal hospitals, zoos, and government agencies. Subject To: https://www.antechdiagnostics.com/privacy-policy , https://www.antechdiagnostics.com/terms-of-use

Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole cell engineering reconstructing complex molecules in yeast to bring to market next generation plant inspired medicines. Antheia’s team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.

Antibodies Incorporated is a biotechnology company that specializes in manufacturing and distributing monoclonal and polyclonal antibodies, diagnostic reagents, diagnostic kits, and developing ImmunoAssays.

Antibody Solutions is a privately held American contract research organization that helps biopharmaceutical companies advance their discovery of better diagnostics and therapeutics by delivering fit-for-purpose antibodies. The company provides comprehensive project management and technical support in a fee-for-service model. Antibody Solutions has expertise in immunology, immunochemistry, biochemistry, molecular biology, cell biology, transgenic animal platforms, flow cytometry, recombinant expression, and bioreactor technology. Antibody Solutions has served more than 500 clients, including all of the top 10 global pharmaceutical companies. Founded in 1995, the company is headquartered in Santa Clara, Calif. and works with clients worldwide. A leading developer of therapeutic, biomarker and critical reagent antibodies, Antibody Solutions provides elements vital for successful antibody discovery, including: Antigen design and generation Monoclonal and polyclonal antibody generation Monoclonal and polyclonal antibody production and purification Biological characterization (sensitivity, specificity, agonist/antagonist activity, internalization) Physico-chemical characterization (affinity, amino acid sequence, purity) Conjugation of antibodies and proteins Antibody engineering and recombinant expression Analytical methods development (ELISA, Flow Cytometry, PK/PD, ADA, Flourescence-Activated Cell Sorting) The company offers 24/7/365 online project management and tracking service.

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes.

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3). The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.

Apeel's evolving technology stack is built on an unprecedented understanding of produce quality and shelf life. This has only deepened as the use of data and technology have given partners a powerful way to accurately and efficiently evaluate produce for ripeness, freshness, and other attributes. Apeel is developing science-backed, technology-supported solutions that help improve the produce experience on shelf.

Apeximmune's mission is to harness the power of the immune system to treat cancer and autoimmune disease. We focus on discovering and pioneering powerful therapeutic antibodies against innovative targets that shift the balance of immune cell activity and deliver lasting, transformative medicines.

Apex Medical Technologies is a healthcare company that specializes in non-latex elastomeric thin film dip molding, offering synthetic alternatives to replace latex-based products.

Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Applied Biomics is a proteomics service company that provides top-quality, cost-effective, and full-line proteomics services to meet customers' research and discovery needs.

Applied Bio Tech Institute is a biotechnology company that develops animal-free health and environmental products, including oral vaccines, animal-free protein products, natural sweetener, and feed enzymes.

Applied Cells, Inc., was founded in 2018 in Silicon Valley to create revolutionary solutions to cell separation and enrichment products, which increase cell separation efficiently by changing how physics is employed in the process. We are supporting industry experts in Cell Therapy Development with MARS® immunomagnetic cell separation Platform. Our innovative, column-free, immunomagnetic cell iso

Applied NanoStructures is a premier supplier of AFM and SPM Probes as well as custom MEMS devices. The AppNano state-of-the-art MEMs foundry is located in the heart of silicon valley. The company was founded by Dr. Ami Chand who has worked in the NanoTechnology area for more than 20 years.

Applied Spectral Imaging (ASI) improves patient care through advanced image analysis. Founded in 1993, ASI is a global leader in the development of imaging and analysis platforms for pathology, cytogenetics, and life science research. ASI's GenASIs™ automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. The GenASIs platform can be used with most brightfield or fluorescence microscope systems and supports manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab. Our GenASIs HyperSpectral™ and HiSKY® platform created the field of hyperspectral karyotyping (SKY) and is still recognized today as the field's most advanced and productive platform. ASI's applications are US FDA cleared for BandView® (karyotyping), FISHView, SpotScan (for CEP XY, UroVysion®, ALK and HER2/neu FISH), and HiPath (for IHC Family: HER2, ER, PR and Ki67). ASI maintains comprehensive patent portfolios in the US, Europe, Japan and other countries. With thousands of Systems deployed worldwide, offices in the US, Europe and Asia, and a network of over 50 distributors, ASI also takes great pride in our outstanding record of service and support. We stand ready to answer your questions and assist you at all times.

Advancing Gene and Cell Product Development Through iPSC and Genome Editing Technologies Applied StemCell strives to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry to assist in the development of breakthrough therapeutic approaches to cure intractable diseases. ASC is a trailblazing CRO/CDMO committed to building a complete iPSC-Gene Editing platform for the production of iPSC-derived products for gene and cell therapy research and development. With the integration of our unique iPSC approach and IP-based site-specific large cargo insertion technology, TARGATT™, we (1) develop immune-compatible master iPS cell lines and (2) deliver large DNA fragments to pluripotent cells that have proven differentiation capabilities. We stand at the forefront of the iPSC-based therapy revolution delivering research- and GMP-grade iPSC solutions along with various downstream assay services. Current Offerings: • iPSC Cell Line Models: iPSC generation, CRISPR & TARGATT™ genome editing, differentiation • Cell Gene Product CDMO: TARGATT™ iPSC Platform for allogeneic cell therapy products/GMP iPSC reprogramming, cell banking, gene editing, and differentiation • Bioproduction: TARGATT™ CHO cell system for antibody screening and bioproduction/TARGATT™ HEK293 cell system for library/antibody screening • Animal Models: Custom and off-the-shelf CRISPR & TARGATT™ mouse models For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

Applied Surgical Robotics is a MedTech company focused on developing robotic technology and SaaS software solutions to improve surgical precision.

Applied Viromics is a biotech company aiming to support early drug discovery and development activities. Applied Viromics specializes in custom-made recombinant viral vectors for efficient gene delivery both in vitro and in vivo.

Apreo Health is an emerging clinical-stage medical device company dedicated to restoring health and quality of life to patients afflicted with severe emphysema, an advanced form of Chronic Obstructive Pulmonary Disease (COPD). In 2018 COPD was the second leading cause of death in United States of America(1) behind Ischemic Heart Disease, with over 8,000 deaths due to emphysema in 2023(2). Apreo Health’s first product, the Apreo BREATHE Airway Scaffold is a novel implant designed to gently release air trapped in affected hyper-inflated lungs. Apreo Health is dedicated to pioneering safe, transformative solutions for lung disease. We serve patients with passion, integrity and a commitment to restoring their health and quality of life. Apreo is a privately held company headquartered in Menlo Park, CA., USA. The BREATHE Airway Scaffold is an investigational device and is limited to Federal (or US) investigational use. It is to be exclusively used in clinical investigations.

With APstem Therapeutics’ breakthrough discovery of Adult Pluripotent Stem Cells (APSCs™), we are on a mission to eradicate difficult-to-heal diseases and conquer the challenges of aging.

Aptitude Vision is a biotechnology company that specializes in developing next-generation synthetic biomolecules for treating vision-threatening diseases by simultaneously targeting multiple pathological processes.

Apton is a California-based biotechnology company that manufactures and supplies single-molecule detection and sequencing imaging systems for clinical applications.

Apurun specializes in tech transfer development and GMP manufacturing services for nanoparticle pharmaceuticals and nanomedicines. Their comprehensive approach enables and supports the development of nanoparticle pharmaceuticals.

Aqtual, Inc. is a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology. Our mission is to revolutionize the treatment and management of these conditions by bridging the translational gap between groundbreaking research and practical healthcare solutions.

Drug discovery remains an expensive and time-consuming process. Promising compounds proceed through clinical trials only to have many fail before FDA approval. Aracari Biosciences aims to simplify this process by more accurately and efficiently evaluating promising drug compounds in a human tissue-on-a-chip model prior to clinical trials. Our​ proprietary, Vascularized Micro-Organ (VMO) platform is the first to contain a 3D, perfused network of living, dynamic human blood vessels that deliver nutrients and drugs directly to tissues just as in the body. Ask about our oncology models that incorporate multiple human tumor types within the vascularized tissue or our blood-brain barrier model for testing trans-barrier transport of drug compounds targeting the brain.

We have invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Our proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, with water as the only byproduct. To learn more, visit us at www.aralezbio.com Aralez Bio is a proud member of Cyclotron Road.

Arbor Vita Corporation (AVC) is a privately held company committed to making a difference by enabling early and accurate diagnosis and treatment of disease. The company has products on the market or in clinical studies to address global health challenges in the areas of HPV-induced cancer and infectious disease. AVC also has a pipeline of products in development.

Arctic Foam works with Algenesis to makesurfboards from polyurethanes isolated from algae.

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries).

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs. We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis'​ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Ardigen is a bioinformatics company that specializes in AI-driven solutions for drug discovery and precision medicine.

Argonaut Manufacturing Services is a contract manufacturing company that provides supply chain technologies for biopharmaceutical, diagnostics, and life science organizations. They offer services such as aseptic fill finish manufacturing, IVD manufacturing, and high-yield manufacturing. The company is dedicated to serving highly innovative companies in the industry.

We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.

Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR).

Arima-HiC is a proximity ligation method that captures the three-dimensional organizational structure of chromatin, where genomic sequences that are distal to each other in linear distance can be closer to each other in the 3D space. The high-resolution, genome-wide map of interacting genetic loci that is generated from Hi-C data can then be used across multiple genomic applications including identification of promoter-enhancer interactions for gene regulation studies and scaffolding contigs for genome assemblies to define chromosomes de novo.

Arine is a leading AI-powered medication optimization platform that improves patient outcomes and reduces healthcare costs by ensuring that patients receive the most effective and appropriate medications. By integrating advanced analytics with deep clinical expertise, Arine provides timely, personalized recommendations, enabling health plans and at-risk provider organizations to enhance medication safety, adherence, and effectiveness among their members.

Cell-Free DNA Testing

Arisan Therapeutics Inc. is a biotechnology company based in San Diego CA committed to the discovery and development of broad spectrum orally active small-molecule anti-infectives. Current programs include a number of antiviral and antibacterial discovery projects.

ARIZ Precision Medicine is pre-clinical stage company aiming to selectively target and destroy early-stage drivers of cancer, such as the deregulated PRDM genes and proteins that were previously deemed “undruggable”. ARIZ set out to prove that cancer cells with PRDM abnormalities could be individually targeted and destroyed without harming normal cells by utilizing knowledge of the PRDM gene family, proprietary siRNA constructs and innovative drug delivery nanotechnologies to target these cancer cells. Proof of principle studies confirmed that this approach selectively killed multiple types of cancer cells (breast, colon, lung, myeloma, etc.) thus ARIZ is continuing in the development of new drug candidates for cancer by pushing these products to testing in animal models of cancer. This will give ARIZ compelling data and intellectual property to share with pharmaceutical companies and, thus, enter into strategic partnerships to take our products to the clinic and then to market. Ultimately, through these efforts, ARIZ intends to cure cancers in a way that preserves a patient’s quality of life and avoids the harmful and adverse effects of current therapies. ARIZ is located in Davis, California and benefits from the combined knowledge of a board of experts in PRDM genes, drug delivery and drug development.

ARK Diagnostics Inc. designs, manufactures, and distributes in vitro diagnostic products. ARK's proprietary assays accurately measure drug levels in biological fluids. Clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. By optimizing drug levels, clinicians improve outcomes, reduce toxicity, and lower healthcare costs. ARK is dedicated to improving the quality of patient health through better therapeutic drug management. (ARK Diagnostics, Inc. seeks regulatory clearance in the United States and Internationally.)

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Harnessing the power of RNA biology to find treatments for patients with unmet medical needs. Advance and utilize the cutting edge antisense technology (siRNA and ASO) to discover and develop next generation medicines for both large and rare disease indications.

Arrayit develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

ArsenalBiosciences, Inc., is a privately held, clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

Was SilverBack Therapeutics, merged with ARS Pharma in 2023 ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including food, medications, and insect bites. The company was founded in 2015 and is based in San Diego, California.

Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 700+ healthcare systems and federal agencies to facilitate approximately 2.2 billion messages annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience. Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for four consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

Arterys was founded to facilitate the global advancement of medicine through data, artificial intelligence and technology. Because a significant proportion of the world's medical data resides in medical images, Arterys set out to tackle several issues around the space, including the enormous workloads radiologists face, the lack of accuracy with many of today's tools, and the need for increased consistency across practices. The company was the first to receive FDA clearance for a cloud-based product with Artificial Intelligence, and currently has 8 FDA clearances, and is active in 118 countries. Arterys continues to focus on solving some of radiology's most pressing needs. We deliver the most comprehensive set of clinical AI solutions in the industry, built off a single platform and user interface that focuses on users with seamless workflow integration and a unified and optimized UI for every one of our applications. By making imaging diagnostics quantitative, intelligent and available, we empower healthcare organizations to improve physicians' experience, patient outcomes, efficiency, and reduce costs with cloud and AI. Arterys has offices in San Francisco, Calgary and Paris. For more information, please visit www.arterys.com. Follow Arterys on Twitter at @ArterysInc at https://twitter.com/ArterysInc.

Artery Therapeutics, Inc. (Artery), a biotechnology company headquartered in the San Francisco Bay area, develops proprietary therapeutics for mainly neurodegenerative diseases including apolipoprotein E (ApoE4) associated dementia and Alzheimer's disease. Artery¹s novel peptide library is derived from ApoE. Our safe and effective peptides are designed to manipulate the ABCA1 (ATP-binding cassette) transporter, thereby altering cell membrane composition and functionality of monocyte-macrophage cells including glial cells in the brain. CS6253, the clinical candidate for neurodegenerative diseases, shows favorable safety profile and pharmacokinetics in IND-enabling studies and human studies are ongoing in subjects with and without the risk factor APOE4 sponsored in part by NIH-NIA and Alzheimer’s Association Part the Cloud.

Arthrosi Therapeutics is a leading clinical-stage biotech company dedicated to advancing therapies for gout disease. Our proprietary oral drug candidate, AR882 which is currently in clinical Phase 3, has demonstrated unprecedented sustained urate lowering in gout patients and reduction of tophi, showing exceptional potential to treat millions of patients suffering from gout and tophaceous gout. At Arthrosi Therapeutics, we are committed to transforming the treatment landscape and improving the lives of patients worldwide.

Revolutionary speech therapy tools for parents and speech therapists. Simple to use & works twice as fast as traditional methods.

Recombinant T Cell Receptor Ligands

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.

The company supports cell and gene therapy manufacturing and process development projects from design through to clinical and commercial scale.

Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

ASC Therapeutics focuses on the development of curative therapies for rare diseases. Our gene, CRISPR and cell therapies were developed at Applied StemCell, a life sciences company for over 12 years, including proprietary gene editing technologies. Our development pipeline includes several preclinical stage projects focusing on monogenic blood disorders that exhibit a high genetic penetrance and conditions requiring immunomodulatory interventions. Contact us for partnership opportunities

Founded in 2018, Asegua Therapeutics LLChas launched an authorized generic of EPCLUSA®(sofosbuvir/velpatasvir) and an authorized generic of HARVONI®(ledipasvir/sofosbuvir).

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

āshibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease.

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

Aspa Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on developing a treatment for Canavan disease, a devastating inherited condition without an FDA-approved therapy. Aspa is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe and effective treatment for Canavan disease to patients as quickly as possible.

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Aspira Scientific was founded by scientists coming from diverse functional areas (marketing, business development, R&D, manufacturing) with a common passion for science and quality. We believe in the power of human curiosity and the importance of scientific endeavors when applied to essential fields such as medicine, crop protection, materials, etc. Aspira Scientific strives to 1) provide highly cost-efficient research and development solutions while meeting the market-expected quality standards and 2) provide greater access to novel research tools through participation in a truly global innovation ecosystem. Through this collaborative relationship, we aim to foster a "thriving" research environment and deliver the next scientific breakthroughs for the betterment of humanity.

Since our inception in January of 2006, Assay Biotechnology has been a worldwide contributor of industry-leading antibody and assay technologies, fluorescent dyes, quenchers, recombinant proteins and synthetic peptides. Located in the heart of California's San Francisco Bay Area, we have strived to answer the global need for high quality assay kits and immunological reagents used in academic and pharmaceutical research that formulate the basis of healthcare. For the first couple years after our founding, Assay Biotech established itself as an antibody manufacturer, catering specifically to large corporations through OEM partnerships. Since then, we have been emerging as a prominent assay and antibody source, expanding our reach to millions of researchers in over 50 countries around the world. We are determined to become one of the world's leading assay development and manufacturing companies, providing a multitude of ready-to-use assays, immunological reagents, molecular detection modules and biomarkers to support the most arduous academic and pharmaceutical research endeavors.

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle.

Astute Medical is a healthcare company that specializes in identifying and validating unique biomarkers to rapidly assess high-risk acute conditions and diseases, supporting healthcare professionals with useful clinical tools.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.

Atengen is developing drugs that specifically target the tumor blood vessels of most solid tumors. The long-term goal is to develop a new generation of drugs that can be used in combination with existing cancer therapies to improve patient outcomes.

At Athelas we're bringing simple, life-changing health care products and medical billing services to patients and providers around the globe. Athelas Revenue Cycle Management (RCM): Billing and reimbursement don't have to be painful. Athelas RCM delivers world-class service, maximizes reimbursements, and delivers actionable insights into the financial health of your practice. Athelas prides itself on end-to-end revenue cycle management. This means we cover all aspects of RCM besides simple submission - include denials, working A/R, research, and more as the backbone of your healthcare business. Athelas has powered revenue intelligence for hundreds of healthcare businesses, from small clinics to large health systems. Athelas Remote Patient Monitoring (RPM): We allow healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

Athena Discovery is a contract research organization (CRO) for biotech and pharmaceutical companies specializing in non GLP drug discovery services with a focus on virology and immunology.

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for Inflammatory Bowel Diseases, lupus, and cancer. The company is focused on developing precision therapeutics for novel & specific subtypes of patients.

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

Atlas Data Storage is a technology company building end-to-end DNA data storage.

Developed a proprietary platform that holds the potential to discover novel structure targets across the transcriptome and for the design of RNA-targeted small molecules, RNA-based medicines and RNA tools.

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

Dedicated to the next-generation toolset for left-heart access.

Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.

Auctus is developing a dynamic vertebral body tethering system to treat pediatric scoliosis with an adjustable non-fusion system

Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

AuST is a medical device design, development, and manufacturing firm specializing in minimally invasive medical devices. We excel at collaborative development and have taken numerous products from concept to market using a process that focuses on rapid design iteration and ample clinical feedback. Our design expertise is supported by in-depth experience with quality management and US and European regulatory systems. We maintain a fully resourced product development lab and pilot production facility in Mountain View, California. We also maintain volume manufacturing capability in Salt Lake City, Utah. In addition to our development capabilities, we offer a number of novel technologies that can enhance device performance and manufacturability.

Research product distributor, Contract Services

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people. We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression.

AutoGenomics is a biotechnology company that offers an automated microarray based multiplexing molecular diagnostic platform to assess disease signatures with novel genetic biomarkers in the areas of women’s health, cancer and personalized medicine.

Autonomic Technologies is a medical device company that focuses on the development and commercialization of innovative therapies for autonomic disorders, particularly severe headaches.

Autonomous Medical Devices Incorporated (AMDI), with its principal place of business in California, employs a world class team of engineers, scientists, clinicians, and manufacturing experts dedicated to the development and manufacture of point-of-care diagnostic devices using breakthrough microfluidics, protein engineering, and data/cloud connectivity. AMDI will launch its first products from its ISO:13485 certified 110,000 square foot facility in Santa Ana, CA.

AVACEN Medical is a healthcare technology company that specializes in noninvasive medical devices for pain management, offering drug-free alternatives for various chronic and acute conditions.

Avails Medical, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and health-care associated infections.

NeoMed develops innovative enteral collection and delivery products supporting the specialized feeding and medication dosing needs of the low birth weight, neonatal and pediatric patient. We are committed to improve patient outcomes through product designs that meet safety, clinical, and regulatory guidelines while supporting cost containment objectives.

AvantGen is a biotechnology company dedicated in accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Based in San Diego, the fun and collaborative team is steadfast in this pursuit.

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

Aveni Foundation is a biotechnology company that focuses on expediting the development of gene-targeted therapies for cancer and Parkinson's disease.

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.

Avenu Medical is a well-established medical device company dedicated to creating a paradigm shift in vascular access for hemodialysis patients. Our focus is to pursue unmet clinical needs by developing a minimally invasive, cost effective and efficient approach to vascular access. Founded in 2010 and headquartered in Orange County, California, we have developed the Ellipsys® Vascular Access System, an innovative, image-guided, single catheter system used to percutaneously create an arteriovenous (AV) fistula for hemodialysis access. Over the past three years, the Ellipsys System has been used in clinical trials outside the United States. In December 2014, we received approval from the Food and Drug Administration (FDA) to begin a pivotal Phase III clinical trial in the United States through an Investigational Device Exemption (IDE). Patient enrollment for the trial was completed in June 2016. The Ellipsys System has received FDA approval and European CE Mark approval for the creation of an arteriovenous fistula in patients with chronic kidney disease requiring hemodialysis.

Avenzoar Pharmaceuticals is a start-up pharmaceutical company founded in 2016. Avenzoar is specialized in developing cancer drugs aiming at targeting and

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of oncology therapies for patients.

Aves Labs produces high-affinity, custom chicken IgY and other immunoreagents for biomedical research and antibody manufacturing.

Avid Bioservices (NASDAQ:CDMO), is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology, biopharmaceutical, and cell & gene therapy industries. With over 30 years of experience, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Avid Bioservices positions are accessible via the Avid Bio Careers page at https://avidbio.com/careers/.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company’s lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in PAD patients.

Aviva Systems Biology specializes in providing polyclonal and monoclonal antibodies, ELISA kits, proteins, and custom services for research needs. We manufacture 24,000 validated polyclonal antibodies and offer nearly 20,000 ELISA kits. Our custom laboratory services include protein expression and purification, antibody development, and ELISA development, validation, and production. Our head office is in San Diego, CA, we also have an office in Beijing, China. Both locations provide scientific support assisting researchers with a variety of proteomic objectives. Aviva provides unique tools for research associated to unique species and targets. The company's products are relevant to 10,000 unique species, 10,000 cellular processes, and 5,000 protein pathways. Research Areas Transcription factors, cancer, cardiovascular, cell biology, DNA damage and repair, epigenetics, signal transduction, cell differentiation, stem cell biology , and many more. Specialties Western blot, immunohistochemistry, ELISA, custom protein expression

Axbio is a semiconductor-biotechnology company, developing cutting-edge technologies including nanopore sequencing, Bio-CMOS chips, and electrochemical sensors. Its sequencing and molecular diagnostics products are suitable for academia and industry users, serving large research laboratories as well as small clinics.

Axcess Surgical is a medical devices company that specializes in creating advanced surgical innovations for optimum results.

Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.

AxisPharm is a San Diego based antibody drug conjugate (ADC) linker product and service provider. At AxisPharm, we focus on manufacturing novel ADC linkers, site specific molecular probes and advanced biochemical reagents. We also provide a variety of bio/chemical services worldwide, including custom synthesis and integrated drug discovery services.

Axonics Modulation Technologies, Inc is a privately-held medical device company developing an innovative neuromodulation platform based on miniaturized rechargeable technology. The Axonics Sacral Neuromodulation System™ is the first CE-marked rechargeable SNM system designed to improve the experience of both clinicians and patients suffering from Urinary and Fecal dysfunction (not available in the US).

Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms

Symphony Ayasdi is a FinTech company that specializes in AI-driven machine learning and data analytics solutions for financial services.

We believe good oral care is critical to everyone’s health and wellness. Dental professionals and consumers alike should have access to technologies that improve oral health. We are committed to the belief that these technologies should be proven effective through empirical evidence, have elegant & intuitive design, and be as minimally invasive as possible. At Azena, every insight is given a chance to develop, to be validated by science and clinical research, and to inspire the creative minds of our designers and engineers. We continually challenge ourselves to explore innovation for the betterment of oral healthcare. We base our innovation on the foundations of science and aesthetic design to create effectiveness, simplicity, ease-of-use, and overall appeal. With a focus on improving oral healthcare, we design, develop, validate, manufacture, and market world-class devices for both dental clinicians and consumers. We are continually searching for new solutions to enhance oral care. Our offerings are created at the intersection of where art, science, and technology meet.

Azora Therapeutics is a pharmaceutical development company developing novel therapies for serious autoinflammatory diseases like hidradenitis suppurativa.

Bakhu Holdings, Corp. produces, manufactures, and sells cannabis-related byproducts for medical, food additive, and recreational use. The company was founded in 2018 and is based in Long Beach, California.

We are Basilard BioTech. We have introduced our novel gene delivery technology platform, Celletto™ to transform the rapidly growing cell-based therapies market. Celletto™ is a differentiated & superior solution for non-viral gene delivery. Cell and Gene Therapies (CGT) have immense potential to address unmet clinical needs by leveraging the power and diversity of cell functions. They offer the best hope for finding solutions to prevailing diseases that affect and kill millions of people. The main challenges now are improving upon the limitations of biological and ex-vivo gene delivery and scaling manufacturing (cost-effectively) to meet the needs of current/future cell therapies. This is the bottleneck Celletto™ addresses with our new, disruptive, IP-Protected mechanoporation solution that offers a better, mechanical (rather than biological), approach to gene delivery. In ex-vivo delivery, Celletto™ consistently achieves higher transfection and cell viability performance and yields vs. the industry leading bulk electroporation platform currently used widely. In viral delivery, Celletto™ provides greater scalability, safety, efficiency, & versatility than prevailing viral delivery methods, as well as lower cost & lead time. And Celletto™ is a superior platform for primary T cell engineering than both electroporation and the prevailing viral delivery methods.

BABEC provides assistance to Bay Area schools and equipsteachers with the technical skills and pedagogical knowledge to teach biotechnology.

The company providesservices inbioanalytic, molecular and cellbiology, in vitro and in vivo pharmacology.The company's capabilities include assay development and in vitro/in vivo pharmacologystudies forantibodies, small molecules, siRNAs, proteins, and gene therapy products.

BCN Biosciences is a privately held pharmaceutical company with core competency in oncology drug development. BCN is currently developing novel small molecule drugs for the treatment of cancer.

Beeflow creates nature based solutions to help farmers improve the impact of pollination in agriculture by leveraging scientific knowledge and technology. Pollination is critical to crop success as it sets the ceiling for crop yield and quality potential. Inefficient or lack of pollination can reduce crop yields, cause malformation and small-sized crops, contribute to fruit diseases and ultimately increase food waste.

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, the materials we wear, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the development of breakthrough products and accelerate time to milestone and market. Come help us bring modern software to modern science. https://www.benchling.com/careers/

Benchmark Research, an Avacare business, has a track record of safety and expertise, having conducted more than 1,000 trials since 1997 at clinics located in California, Louisiana and Texas. Benchmark's superior team of motivated and focused investigators offers clinical trials experience in a wide range of therapeutic areas. Our knowledgeable investigators enthusiastically embrace clinical research and the opportunities that new therapies bring to the marketplace and patients. Dedication and experience aside, our investigators are also highly trained in GCP and FDA regulations.

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec is using its technology, called DNA-directed RNA interference (ddRNAi) to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases , including oculopharyngeal muscular dystrophy (OPMD) and hepatitis B. By combining the specificity and gene silencing effect of RNAi with gene therapy, ddRNAi has the potential to produce long-lasting silencing of disease-causing genes from a single administration, which could minimize the requirement for patients to take regular doses of medicine. Benitec’s objective is to become the leader in discovering, developing, clinically validating and commercializing ddRNAi-based therapeutics for a range of human diseases with high unmet clinical need or large patient populations and, as a result, provide a better life for patients with these diseases.

The company helps customers' businesses become more sustainable and compliant while lowering their cost and/or optimizing their supplies of both water and energy.

Berkeley Yeast uses synthetic biology and process engineering to develop products with transformative impact on fermentation, particularly in the beer and wine sectors. With proven traction in these markets, and with support from government grants (NSF, NIH, USDA) and venture capital, we are expanding our research and manufacturing pipelines. Currently available products in the market give unprecedented control over flavors and improve production efficiency. And that's just the beginning. We are hiring—come join our team to build the future of fermentation. Learn more about our company and products here: Why Genetically Modified Yeast Could Be the Next Step in Beer's Evolution https://www.goodbeerhunting.com/blog/2020/1/13/yeast-of-eden-why-gmo-yeast-could-be-the-next-step-in-beers-evolution 6 Beer Industry Trends to Watch in 2022 https://daily.sevenfifty.com/6-beer-industry-trends-to-watch-in-2022/

3/21/23- Acquired IsoPlexis Corporation (Nasdaq: ISO) then renamed to create PhenomeX. On Aug. 17, 2023, PhenomeX and Bruker entered into a merger agreement. Berkeley Lights is a leading functional cell biology company focused on enabling and accelerating the rapid development and commercialization of bio-therapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are for research use only. Not for use in diagnostic procedures.

Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insulin delivery device in the market and offers the potential to substantially improve overall outcomes across broad populations of PWDs. To learn more, visit www.betabionics.com. For safety information, visit: www.betabionics.com/safety.

BetterLife is a different kind of life insurance company. We're a member-owned company that offers reliable and affordable life insurance protection, friendly service, and knowledgeable guidance, as well as member-exclusive benefits at no extra cost to you. In January 2021, two member-owned life insurance companies with similar histories came together to form BetterLife, a different kind of life insurance company. Both companies were founded over 115 years ago by "average", hardworking Americans with the goal of providing affordable protection to families in their communities. Members of both societies came together to socialize, have fun, and help others. BetterLife honors our rich, combined history by continuing to focus on what's best for our members, while also finding new ways to serve you and your community. When you become a part of the BetterLife family, you're joining a community that will help you live a better life. BetterLife is headquartered in Madison, Wisconsin. BetterLife also has three agency locations throughout Wisconsin and South Dakota: Plymouth, Wisconsin; Wausau, Wisconsin; and Spearfish, South Dakota. BetterLife is authorized to conduct business in 17 states (AZ, CO, IL, IA, KS, LA, MI, MN, NE, ND, OH, OK, SD, TX, WA, WI, and WY) and is currently conducting business as BetterLife Insurance Company in OR.

By shifting from animal to plant-based meat, we can positively impact four growing global issues: human health 💪, climate change 🌎, constraints on natural resources 🌱, and animal welfare 🐮. #GoBeyond

Bigfoot Biomedical is a new kind of medical device company developing technologies to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes. With an intense focus on ease of use, Bigfoot will optimize the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. The company's pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. Bigfoot will be the first company to deliver a monthly subscription-based service leveraging a smart, connected insulin dosing platform to meet the needs of a diverse population with insulin-requiring diabetes. Bigfoot's investigational system is comprised of best-in-class proprietary and licensed components holistically and securely integrated, leveraging intuitive design, machine learning, and a mobile app running on an off-the-shelf smartphone, all designed to keep glucose levels in an optimal range. "The net result is a company that brings something unique to the table: a remarkable depth of knowledge and technical know-how combined with the personal motivation and direct patient experience necessary to really make a difference in this space." ---The MedTech Strategist, October 24, 2016

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

Bio4t2 is a clinical stage bio pharmaceutical company developing novel single-target and combo-therapeutic CAR based cell therapies against solid cancers through its proprietary PrismCore platform that are fine-tuned to comprehensively target self-antigens in patients with solid tumors.

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.

BioAmp Diagnostics is committed to preventing the misuse and overuse of antibiotics in healthcare through the development of innovative diagnostic tools, that will give medical providers the information they need to correctly treat an infection.

BioAtla is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics™ (CAB) are designed to target and treat cancer with greater precision and fewer side effects.

Bioblocks Magyarország Kft is a medicinal chemistry research organization that serves as a chemistry CRO focused on drug discovery and development candidates.

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Biocare Medical LLC is an innovator in automated immunohistochemistry (IHC) instrumentation, and the full range of reagents for IHC and in situ hybridization (ISH; RISH) testing. Biocare pioneered multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption and cost by 50% or more. Multiplex IHC allows pathologists to visualize more than one marker on a tissue at a time, allowing higher confidence for critical differentiation. Biocare's intelliPATH FLX is the only completely open, continuous random access IHC instrument available. The company’s customers come from clinical and research environments that do tissue based testing and include histology laboratories, pharmaceutical and biotechnology companies; CROs; and academic, government and military labs. Biocare Medical offers an expanding portfolio of products for the rapidly growing cancer and infectious disease diagnostic and research markets. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network. See biocare.net and slidestainer.com for more information. NOTE: Biocare Medical, the Biocare Medical logo, and intelliPATH are trademarks of Biocare Medical LLC.

BioChain is the world leader in high quality processed bio-sample products and analysis services used in advancing translational medicine, companion diagnostics, and clinical product research and development. BioChain's products are available for DNA and RNA sequencing, PCR and RT-PCR, gene expression analysis, DNA and RNA purification, protein extraction and purification, protein expression analysis, and liquid biopsy studies. BioChain's One-Stop Services for Next Generation Sequencing (NGS), from clinical sample collection, sample preparation, sequencing to bioinformatics analysis, will revolutionize the industry. In addition to our world-class bio-specimen and sample preparation line of business, BioChain is moving into the clinical applications that offer clinical genomics diagnostics products and clinical trial services in cancer and reproductive health. BioChain is committed to achieving the Highest Quality products and services at highly competitive prices through our Continuous Process Improvement Initiatives. BioChain established a comprehensive quality assurance program to meet our customers' satisfactions as well as maintaining both ISO 9001:2016 and ISO 13485:2016 certifications for our in house production facilities. Innovation and Collaboration: As an industry leader, BioChain is always striving to innovate and collaborate with the world's leading Pharmaceutical, Bio Technology, and Health Care organizations. We have a strong in-house scientific team and actively seek research and business partnerships with industry innovators and leaders.

BioCheck develops and manufactures high-quality immunoassay kits for the worldwide healthcare markets in their cGMP and ISO 13485 certified facility in the San Francisco Bay Area. BioCheck also provides custom immunoassay development and contract manufacturing services to the diagnostic and research industries.

Biocidium’s primary focus is the development of antibiotics to treat serious multi-drug resistant (MDR) gram-positive and gram-negative bacterial infections. Biocidium maintains strong antifungal and oncology programs and continues to build positive results in areas of skin treatments including psoriasis, acne, shingles and eczema.

BioCorRx Pharmaceuticals is a subsidiary of BioCorRx Inc. (OTCQB: BICX). The company was envisioned and setup with the aim of providing new options for Medication Assisted Treatment (MAT) for the treatment of substance use disorder. We are committed to developing treatments for opioid/alcohol use disorders as well as other related disorders. Our team of experts and industry leaders have a passion for helping individuals suffering from substance use disorder and to enable the medical professionals who can treat them. Our lead product candidate is BICX104; It is a long-acting naltrexone implant that can last several months and is being developed for opioid and alcohol use disorders. For product candidate updates please visit biocorrx.com.

BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. Our mission is to enable scientists to eliminate disease and suffering through novel application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the microarray informatics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. Our employees are excited about solving difficult problems and enabling scientist to make significant scientific breakthroughs. Our passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system for clinical applications enabling research findings to make direct impact on patient care. BioDiscovery is an equal opportunity employer with great benefits and a friendly, high-energy atmosphere. The company is headquartered in sunny Southern California near the Los Angeles International Airport (LAX) and has European headquarters in Cambridge, UK. We are always looking for talented individuals, eager to make a real difference, to join our company.

For over 29 years, BioDot has developed proprietary, quantitative technologies for the dispensing of low volumes of fluids (picoliter to microliter) that meet the needs of industrial, life science, diagnostic, and medical products. BioDot is division of ATS Automation - Life Sciences Division On March 24, 1994, BioDot established itself as a company in Southern California with its patented BioJet™, "Drop on Demand"​, non-contact, dispensing technology. At that time, BioDot focused on using this technology to dispense discrete drops, or a series of drops to form a line. This quantitative, enabling technology was used predominantly in Lateral Flow Test or Flow Through Test applications in the diagnostic marketplace. Over the following years, BioDot expanded its expertise outside of dispensing, and developed lamination and cutting technologies. In parallel, it expanded its application abilities to enable scientists to utilize the quantitative dispensing and develop more sophisticated point of care tests, such as: - Glucose or other Microfluidic Sensors - Immunoblots or Allergy Tests - Cell, DNA, or Protein Arrays - Compound Handling In addition, BioDot developed modular workstations and enabled customers to work in either a "Batch"​ or "​In-Line"​ Approach, depending on their materials and processes, as well as short and long goals. Now, in our 25th year, BioDot continues to be a leading supplier of system tools for the research, development and commercialization of diagnostic tests. With our continuously expanding product portfolio, BioDot has marketed systems for the development and manufacture of Microfluidics. We also have systems for the Life Sciences and the Molecular & Point of Care Diagnostics. By expanding our global presence with entities in China and the UK/Europe, BioDot has a commitment to fully understand our customer's requirements, globally. #lateralflow, #biosensor, #labonachip, #biochip, #dispensing

BioDuro-Sundia, an Advent International portfolio company is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 28 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US with operations in China, totaling 2,000+ employees and 7 global sites across 6 cities. Core expertise includes small and large molecule discovery, development and scale-up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Science-driven, customer-oriented, flexible, people-focused culture enables us to provide top-tier integrated, fast and flexible tailored services to our customers to meet their unique needs and accelerate our development timeline. For more information about BioDuro-Sundia, please visit our website at www.bioduro-sundia.com

BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics. Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics™ pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only eradicate cancer cells, but also protect the patient from relapse and recurrence, through a durable immune response that prevents the development of new cancers, even in the face of new challenges from disease.

BioFluff is working to revolutionize the textile industry by pioneering a new era of plant-based alternatives to animal and synthetic derived materials. Their first product, Savian, is a plant based fur.

The heart of BioFluidica's CTC (Circulating Tumor Cells) system, is a highly efficient CTC capture bed, comprised of 50 to 500 sinusoidally-shaped channels. These channels are coated with antibodies, which isolate specific CTCs from whole blood. The antibodies are chemically immobilized onto the surfaces of the capture bed using BioFluidicas patented technology.

Bioforcetech uses pyrolysis to convert organic waste like sewage sludge into biochar. Pyrolysis consists of treating materials with high temperatures in the absence of oxygen. This process neutralizes toxins and has a lower environmental impact than using landfills. Biochar is a type of carbon rich charcoal that can be used in multiple products. Bioforcetech uses biochar as a soil treatment, in inks, and in concrete.

BioForm Solutions is a San Diego-based contract research organization providing services for the analysis of probiotics in the supplement, food and beverage, cosmetic, and agriculture markets. BioForm Solutions offers industry leading, cutting edge flow cytometry assays developed exclusively by the BioForm team. These assays offer a broad spectrum of solutions for the analysis of probiotic samples in most formulations and are supported by a dedicated staff having over 20 years experience in flow cytometry. We strive to improve our customer's probiotic-based products, including accurately enumerating the viability of probiotics, determining packaging effects, and shelf life evaluation. We are passionate about providing the highest quality services at an outstanding value, along with superior customer service and technical support.

BioGrammatics Inc. is an industry leader in the heterologous gene expression of the single-cell, eukaryotic Pichia pastoris yeast. Our mission is to deliver detailed solutions within the research and development field. Specializing in high-quality products and contract services, BioGrammatics Inc. consistently demonstrates how expression is the language of life. We combine expert support services in custom strain construction, transcriptome generation and analysis, genome sequencing and analysis, small scale fermentation, and genome engineering, with a range of direct-to-consumer products. In addition to our proprietary Pichia GlycoSwitch® Strains, Vectors and Kits, we provide a multitude of other strains and competent cell batches, expression vectors, media, and reagents for research, industrial, and academic applications. To learn more about why methylotrophic Pichia pastoris is the right solution for you, please visit http://www.biogrammatics.com/ or connect with us at info@biogrammatics.com.

BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Our medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics, and symptomatic events through an effortless patient experience. The FDA-cleared, medical-grade BioButton® wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical-grade remote care from in-hospital to home. Learn how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services or visit our website at BioIntelliSense.com. 

BIOLASE, Inc. is a medical device company and global market leader in the manufacturing and marketing of proprietary dental laser systems. Our award-winning dental lasers enable dentists and dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and surgical applications. BIOLASE's laser systems are designed to provide clinically superior, patient-friendly results for many types of common dental procedures compared to those achieved with traditional instruments. BIOLASE has sold over 36,200 laser systems to date in over 90 countries around the world.

BioLegend develops antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.

Biolinq has created a new Biowearable experience by using an array of electrochemical sensors so small you can barely feel them. Our metabolic health sensors work together to provide maximum reliability for continuous sensing applications. With the potential of multiple analytes such as glucose, ketones, and lactate, we provide an entirely new user experience with actionable metabolic health insights. Over the next 10 years we intend to bring Biosensing and Biowearables mainstream. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.

Biolog has the tools, services, and support to provide the microbial phenotypic characterization and polyphasic identification capabilities required to produce functionally relevant insights. Our products and services enable characterization of microbial and mammalian cells as well as identification of thousands of species of bacteria, yeast, and fungi. Learn more at biolog.com.

ABOUT Biologics Consulting is a complete FDA regulatory and product development consulting firm for cell & gene therapy, biologics, pharmaceuticals, and medical devices. In the three decades since its founding, Biologics Consulting has become the go-to consulting partner for companies large and small seeking to bring innovative, safe, and effective products to market in the US. Our team of regulatory scientists, FDA consultants, and professional services staff has decades of industry and FDA experience that allows us to provide an unparalleled insider perspective for our clients. OUR DIFFERENCE The Biologics Consulting difference is all about the unique combination of regulatory expertise we have under one roof. Our team has depth of knowledge and breadth of experience across all product types and development pathways. This value proposition allows us to address the full scope of a client's regulatory and product development challenges from preapproval to commercialization. OUR EXPERIENCE AREAS - Biologics - Medical Devices - Pharmaceuticals - Biosimilars OUR SERVICES - CONSULTING – Regulatory, Product Development, Clinical Planning and Quality support. - SUPPORT SERVICES – Medical Writing, e-Publishing & Submissions, US Agent Services, Due Diligence OUR CLIENTS Our clients span the industry, from established multi-national pharmaceutical, biotechnology, and medical device companies to academic and research institutions. We also support small biotech and medical device start-ups. Since our founding, we have professionally services over 4,500 clients from 58 different countries.

Biolumen is a weight-loss and gut health company, on a mission to reverse the negative impact of the Western diet; like obesity, type 2 diabetes and autoimmune disorders. Biolumen's product, Monch Monch, is a highly functional cellulose matrix which entraps calories in the stomach.

BioMap is an AI for life sciences company, unmasking nature’s rules to generate proteins for a wide range of therapeutic and industrial applications. We build super-scale Foundation models supported by access to unrivaled computational power through our strategic collaboration with Baidu, with whom we share our Founder and Chairman, Robin Li. We supplement our AI capabilities with a leading team of scientists, disease experts and cutting-edge high-throughput labs which generate large volumes of high quality proprietary data for our AI models. We partner with pharma, biotechs and industry to enable their discovery ambitions across a wide range of therapeutic and synthetic biology modalities through access to our AI technology platform, with a variety of flexible collaboration models. Our mission is to leverage AI to radically improve lives.

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.

We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System platform to advance a pipeline of novel covalent therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.

Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company’s products are designed to enhance health and well-being, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing. The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians'​ offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic guided therapy and not a drug, it has no drug type side effects.

Biomiga, Inc. is an innovative biotech research and service company based in San Diego, California. Our mission is to provide the highest quality laboratory products while maintaining the best possible service and support to our end-users. Our products maximize efficiency and cost-effectiveness through our cutting-edge technology and process. Biomiga owns the manufacturing process, enabling us to control both the quality of the products as well as the price. Our products are more reliable and effective while often costing less than half the price of our competitors. Biomiga can customize its products to meet a client’s exact specifications and requirements. Biomiga provides full service support to all our clients through the entire process. Our support and sales staffs are available for consultation 24 hours a day, 7 days a week. We stand behind all our products with a full guarantee. Our mission is to ensure our client’s satisfaction. Biomiga emphasizes on product development. Our R&D team is highly trained in the biological sciences to quickly develop new products. Our products have been proven to meet our clients' high demands with greater cost savings and effectiveness. EzgeneTM and ViraTrapTM are just some examples.

Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

By creating a new medical modality of remote-controlled micro-robots called Bionauts™ we can transform the way the biopharmaceutical industry develops treatments, allowing us to engineer the therapeutic index for efficacy and maintain safety.

Since its founding in 1992 Bioneer Corporation has established market leadership in Korea for most of the products it manufactures. Bioneer has built its business by providing researchers with superior, high quality products at excellent value. Over the years, Bioneer has developed a broad range of unique products that provide total genomic research solutions for life sciences research including genomics, nucleic acid-based molecular diagnostics and gene therapy studies. Bioneer has extensive R&D experience in developing new drugs as well as the use of siRNA and drug delivery systems, and provides unrivalled service and support for such tools. For example, through the creation, development, and commercialization of the S. pombe deletion mutant library, Bioneer provides an innovative tool for improving the development of new drugs. The S. pombe library accurately predicts the toxicity of drug candidates for anti-cancer, Hyperlipidemia and also provides molecular level mechanism analysis of natural compound drugs. The company is headquartered in South Korea with an oligonucleotide manufacturing facility in the U.S., a regional office in China, and is supported by a network of distributors throughout the world. For more information, please visit www.bioneer.com.

Bionexus offers a comprehensive line of biomedical products and services for the scientific community.

Bionova Scientific is a dynamic, full service, biologics Contract Development and Manufacturing Organization (CDMO) on a mission to deliver the highest quality process development and manufacturing services to biologic drug development companies around the world. Bionova's renowned scientific expertise and dedication to its customers helps life changing therapies arrive to the market faster and more efficiently. At the heart of Bionova is a team of highly dedicated experts combining strong experience in cGMP biologics manufacturing and process development, with a technology-focused approach and a deep knowledge of the industry. From early stage research material generation to Process Development and GMP manufacturing, Bionova's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients.

Biopartners Inc. is a global biosample management company with operational offices in the United States and Eastern Europe. It is based in Los Angeles, California. Biopartners Inc. provides comprehensive solutions to support scientific projects.

Biopeptide Company offers design, synthesis, and production of quality peptides using t-Boc/Fmoc solid phase and solution phase technology.

Biopico Systems Inc is a leader in the emerging field of interacting multiple organ systems or microphysiological systems technology. This technology will accurately recapitulate human physiology by engineering physiological fluidic flow and organ microenvironment.

BioQ Pharma is a specialty pharmaceutical company that focuses on setting a new standard of care for infusible drugs.

BioQ Pharma is a late stage specialty pharmaceutical company focused on developing.

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company’s targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Biosapien is a late-stage pre clinical company focused on novel drug delivery platforms.

Our company is uniquely positioned with a multi-facetted experience team in biologics and biosimilars. BioSciencesCorp and its affiliates have the speed of small company with a depth of biologics experience from molecule selection to full commercialization.

The Biosero Green Button Go® suite of software products provides a unified way to design, dispatch, and schedule lab workflows, capturing and managing data all along and across all levels of operation.

Bioserv Corporation located in San Diego, California is a boutique cGMP contract manufacturing organization (CMO) serving the pharmaceutical, biotechnology, life sciences, medical device, and diagnostic industries since 1988. Bioserv’s core competency is manual filling which allows us to be very flexible and capable of handling small to medium batches effortlessly. Bioserv has a broad range of manufacturing suites to meet your production needs. Bioserv’s manufacturing facilities include certified Class 10,000 (Class 7 or Class C), Class 100 (Class 5 or Class A) areas, and Uncontrolled laboratory rooms. Whether a client is looking to move a drug product candidate into the pre-clinical setting, Phase I, Phase II clinic, or looking for basic reagent formulation and filling expertise, Bioserv has the experience and capabilities to get our clients there on time. We have filled a significant number of cGMP finished drug product lots for our clients to support their Phase I and Phase II clinical trial needs. We have a broad level of highly skilled production experts that have worked with very complex formulations, including liposomes, emulsions, nano-particles, small molecules, conjugates, and adjuvants. We understand that each product has its own unique set of manufacturing requirements. Bioserv is committed to making sure that those products are made with the highest Quality Standards each and every time. Work-From-Home Job Scam Alert It has been brought to our attention that job seekers are being contacted by scammers misrepresenting themselves as Bioserv recruiters. These scammers are contacting job seekers on LinkedIn or other job sites asking job seekers to apply for fake work-from-home positions. Please be advised that Bioserv does not generally offer work-from-home positions and all job listings are available here: https://sorrentotherapeutics.com/careers/. Any communication regarding recruitment will be done via email domain ending in @sorrentotherapeutics.co

BioSpyder Technologies has developed a novel product for targeted sequencing called TempO-Seq™, a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. TempO-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. Sample barcoding, together with sequencing short fragments of each gene, enables pooling up to 6,144 samples in one sequencing run. Assay content is flexible and customizable delivering unprecedented accuracy and sensitivity.with simplified data analysis that eliminates the need for bioinformatics. TempO-Seq assays deliver an easy to use solution for customers doing expression profiling for any species.

Biostate.AI is a startup founded in 2023 with the mission of developing generative AI for predictive omics analytics in the healthcare sector. They offer services such as RNA sequencing, DNA sequencing, image sequencing, image data analysis, and more. The company aims to lower costs and increase the utility of RNA sequencing for research and drug discovery.

Biotricity is a global frontrunner in the realm of digital health. Our mission is to bridge the gap between patients and healthcare providers, ushering in a new era of care delivery that is both efficient and patient-centric. At Biotricity, we're not just transforming remote patient monitoring; we're redefining the very essence of healthcare itself. We are proud to offer award-winning health technology seamlessly integrated with state-of-the-art software. With over 100,000 patients placing their trust in us to improve their long-term cardiac health, we have solidified our position as a trusted healthcare partner. Biotricity's remote patient monitoring devices are designed to optimize patient and healthcare provider workflows. Our goal is to provide critical insights into a patient's health swiftly, resulting in faster treatment and improved outcomes. Our advanced hardware and software solutions enable accurate identification of cardiac problems as they occur, transforming the landscape of care for clinics and patients alike. Physicians can now access real-time data with reports in days, not weeks, while patients wear user-friendly, discreet monitoring devices, offering peace of mind throughout the process. At Biotricity, we firmly believe that the future of healthcare lies in connected medical devices that generate data leveraged by both physicians and individuals. We envision a healthcare ecosystem where these devices seamlessly integrate with big data, predictive AI, and machine intelligence, ushering in an era of better and faster analytics for superior care delivery. Join us as we continue to lead the way in digital health innovation, pioneering advancements that are not just transforming healthcare but also enhancing lives. Together, we are creating a healthier and more connected future. Biotricity's stock is trading under the ticker, “BTCY”.

BioTuring is an innovative bioinformatics company based in San Diego. Founded in 2016, the company has developed transformational bioinformatics platforms for sequencing data analysis, enabling scientists to gain valuable insights from biological data in an interactive, fast, and accurate approach. Its product portfolio now covers single-cell and spatial data analysis with BBrowserX, Talk2Data, Lens, BioVinci, and BioColab. BioTuring helps accelerate life sciences and nourishes computational minds.

BioVision is now part of Abcam. BioVision is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. Founded in 1995, BioVision specializes in the supply and integration of high quality imaging technologies to support research. In August 2021, Abcam acquired BioVision for $340 million, and it is now part of Abcam.

Bioxytech Retina is developing a non-invasive retinal oximetry device for earlier detection of diabetic retinopathy prior to the onset of structural damage.

The UCSF Bixby Center for Global Reproductive Health integrates research, training, clinical care, and advocacy to advance reproductive autonomy, equitable and compassionate care, and reproductive and sexual health worldwide.They envision a world where all people have the resources, support, and power to determine their own sexual and reproductive lives. They are a multidisciplinary group of over 200 people with physicians, nurses, advanced practice clinicians, social scientists, clinical researchers, and staff that span UCSF schools and departments. They are in the Zuckerberg San Francisco General Hospital Division of Obstetrics, Gynecology and Reproductive Sciences at UCSF.

Black Sheep Foods is a plant-based meat company that offers a delicious lamb alternative created using revolutionary technology and analytical chemistry, promoting environmental and health benefits.

Blacksmith Medicines is a biotechnology company focused on creating medicines targeting metalloenzymes. They have announced a merger with Forge Therapeutics to further their mission.

Bloom Science is a clinical-stage, central nervous system (CNS) company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs in Dravet syndrome; other rare epilepsies; Amyotrophic Lateral Sclerosis (ALS), a disease that causes nerve cells to die, which breaks the neural pathways, and causes extreme mobility loss over time; and neurodegenerative and cognitive disorders.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.

Specializing in Creating and Improving Biosensors with Synthetic Biology. Winner of LymeX Diagnostics Prize

Blue California is a science-based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural product and nature-inspired industries. We develop novel materials and new clean, green production methods to ensure the successful commercialization of products to companies with global reach. The three divisions of Blue California are Specialty Ingredients, which is dedicated to clean and natural nutritional ingredients. FineCap™ Novel Delivery Systems, the new generation microencapsulation for simplified manufacturing and excellent performance. Sensegen®, the flavor and fragrances comprised of expert perfumers and flavorists to help create clean and sustainable product innovations.

At Blue Evolution, we are revolutionizing sustainability by harnessing the power of seaweed to create innovative solutions for a better tomorrow. As a leader in ClimateTech, we develop cutting-edge products that span biostimulants, animal feed, biomaterials, nutraceuticals, and cosmeceuticals. Our climate-smart biorefinery, powered by renewable energy and green chemistry, transforms seaweed into high-value outputs that drive decarbonization, enhance climate resilience, and promote sustainable growth. We collaborate with leading research institutions and indigenous communities worldwide to advance our mission of creating a regenerative future. Our patented processes and pioneering research set us apart, positioning Blue Evolution at the forefront of sustainable innovation. Join us in leading the charge toward a more sustainable, resilient, and prosperous world.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

Blue Planet Ecosystems builds, develops and operates modular LARA (Land-based Automated Recirculating Aquaculture) systems for sustainable seafood production in extreme environments. We help farmers, agriculture businesses and future entrepreneurs to diversify their farming methods in the face of climate change.

Blueprint Genetics is a genetic diagnostics company focused on inherited diseases. We provide world-class genetic diagnostics and clinical interpretation for hereditary diseases. We are passionate about changing peoples’ lives through development of groundbreaking solutions that take genetic diagnostics from niche to mainstream. Our global team of innovative and motivated people are working at the forefront of genetic knowledge, AI and other areas of life science. Our team consists of more than 20 nationalities working as geneticists, data analysts, laboratory technicians, client service specialists, genetic services consultants, software developers and marketing specialists. Today, we work with customers in over 70 countries and push to make genetic knowledge easier to access for the medical community. Our comprehensive and cost-effective genetic tests support healthcare professionals around the world in providing the best care for patients and families with rare inherited diseases.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Bolt threads usesproteins found in nature to create fibers and fabrics with both practical and revolutionary uses, starting with spider silk. The company also develops materials from mycelium, the vegetative form of mushrooms. One application is a form of vegan leather called "Mylo."

MISSION Bonneville Labs’ is creating a global life science ‘hard tech’ community empowered to go forward, faster. We provide comprehensive and supported environments enabling companies to focus on discovery and outdistance the conventional. BONNEVILLE LABS There’s no need to start from square one. Bonneville Labs is an adaptable workspace that eliminates operational barriers and reduces the cost of development through shared services and pre-negotiated discounts. Backed by years of industry experience, we manage laboratories and services so members can focus on their science. BONNEVILLE LABS COMMUNITY BENEFITS Headquartered in Berkeley, California, Bonneville Labs features flexible lab space from single benches to dedicated suites, lab equipment, streamlined operational support that includes Environmental Health and Safety training and oversight, purchasing services, facilities support, meeting rooms, community lounges, kitchens, high-speed internet, and events. BONNEVILLE COMMUNITY Small teams don’t have to worry about the setup and maintenance costs of a traditional office. They can work like larger organizations at a fraction of the cost in a workspace that can accommodate their needs as they grow. Large companies looking to expand benefit from our streamlined workspace model - sidestepping the costs of building it out, operating it and the long-term liability - while gaining access to pioneering talent. Bonneville Labs’ dynamic environment facilitates cross-pollination while nurturing a unique bio-community that connects innovators from across the broader life sciences community.

Boomerang Pharmaceutical Communications marry the art of creativity with the rigor of science to produce outstanding digital solutions for the pharmaceutical and biotech industries. Their in-house experts cover every dimension of digital communication. They have all the tools, skills and knowledge needed to craft a comprehensive digital strategy

With 30 years of expertise, Boster Bio is committed to producing high-quality antibodies and ELISA kits at the best value for researchers worldwide. Our global distributor network extends beyond 30+ countries and delivers rigorously validated antibodies, ready-to-use kits, and reagents that have received over 60,000 citations. At Boster, our customers' research is our priority. Our mission is to help customers achieve their research goals so that they can stay on the cutting edge of research. To honor our customers' goals, we choose to uphold high quality standards by manufacturing our antibodies and ELISA kits in our very own facilities from start to finish for strict monitoring, efficiency, and optimization. Let us become your partner in research. Get better results with Boster. For more information, please visit www.bosterbio.com.

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive. Our Culture: At Boundless, you’ll experience what it means to be out in front of the wave. Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers. Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless. We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success. At Boundless, we’re all in. We are unbound by convention, bound to save lives. Career Inquiries careers@boundlessbio.com General Information Inquiries info@boundlessbio.com

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; and UC San Francisco. The company was founded in 2015 and is headquartered in Palo Alto, California.

We are an investment banking and venture capital advisory firm that focuses on the healthcare industry. We have relationships with corporate partners, venture capitalists, hedge funds, family offices, and HNWI internationally. We represent companies and venture capitalists in biotech, pharma, diagnostics, devices, and imaging. BUSINESS DEVELOPMENT We listen to clients' goals for financing and do deep research for the right financial partner that includes family offices, angels, venture capitalists, hedge funds, and small funds. We provide personalized venture capital and investment banking advisory services. We keep the number of companies from one to three. We put together co-lead investors to help make the transition go smoothly. We represent multiple companies and venture capitalists in foreign countries looking for a foothold in California and the U.S. We work with U.S. companies looking for relationships internationally. We understand cultural differences and can help bridge the gap of communication on deals. FINANCE Expertise at targeting financial partners internationally. We create extensive relationships with private funding sources—from family offices to strategic angels. We build solid associations with healthcare and technology venture capitalists throughout the world. We comprehend the complexity of creating tranches in an investment. We work with lead investors and help put international syndicates together. We represent venture capitalists and individual companies and we understand the key points of closing deals STRATEGY We understand how to create materials that synthesize the company's strengths and message. We work with multiple CEOs and help design winning and concise pitches while providing personalized assistance on each call with investors and find areas that can be improved. We research influencers and non-profits in the scientific community that can help sway financiers' opinions. We analyze the current venture market for your company and find out which other companies in your space are getting financed and why. We design multi-tiered strategies of creating associations with the best financial partners.

Brightseed is a pioneer in biosciences and artificial intelligence (A.I.) that illuminates nature to restore human health. Brightseed’s proprietary A.I., Forager®, accelerates bioactive discovery, biological validation and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Through Forager® and clinical evaluation, Brightseed partners with organizations across the consumer health continuum to offer insight into the world of bioactives and health solutions. Brightseed produces branded, proprietary, clinically proven bioactives that are sold to leading dietary supplement, food & beverage CPG, specialty nutrition and medical food companies for incorporation into health beneficial consumer products. Visit www.brightseedbio.com to learn more.

Bright Uro is an early-stage medical technology company headquartered in Irvine, CA. They are building the next generation of diagnostic devices for Urology.

BroadPharm is a leading customer-focused biotech company. We are dedicated to manufacturing and supplying high-purity PEG Linkers, Click Chemistry Tools, ADC Linkers, PROTAC Linkers, Drug Delivery Lipids, and Labeling Reagents to our clients worldwide. Founded in 2009, BroadPharm takes our customer needs as our highest priority. We have over 8,000 PEG Linkers, Click Chemistry tools, ADC Linkers, Lipids, Fluorescent Dyes, and Nucleosides. In addition to our broad catalog selection, we also offer IP-protected custom synthesis and bio-conjugation services for our clients in the pharmaceutical and biotech industries. We provide timely technical support to address our client's needs and offer technical advice for the best use of our new products. With our strong expertise in modern chemistry along with innovative and novel Lipid & PEG technology supported by state-of-the-art equipment, BroadPharm can help our customers accelerate their research through cost-effective and efficient solutions.

Broadwing Bio is advancing antibody therapies to treat common causes of vision loss. Focused on genetically validated targets, our goal is to develop best-in-disease therapies to meaningfully preserve eyesight for glaucoma and geographic atrophy patients.

Bruker Spatial Genomics, Inc, (formerly Acuity Spatial Genomics, Inc.) provides a groundbreaking platform for simultaneous, genome-wide visualization of the 3D genome in single cells and opens new frontiers in spatial multiomic analyses for discovery. Based on patented technologies developed at Harvard University, the company’s jebFISH™ technology empowers researchers to directly visualize genome organization and 3D chromatin architecture of individual cells, directly in situ. The company’s transformative PaintScape™ platform, powered by jebFISH technology, breaks through challenges of multiplexed, direct imaging of the genome in nuclei and makes it possible to gain critical insight into cell programming and transcription regulatory programs that drive cell type, state, and function. Directly seeing changes and disruptions of genome organization will elucidate mechanisms of disease and its progression especially in disease systems like cancer. Bruker Spatial Genomics, Inc. is part of Bruker’s strategic investment in spatial biology and its initiative to develop and expand emerging spatial analyses technologies. The PaintScape platform joins the portfolio of high-performance Bruker Spatial Biology platforms that empower researchers to delve deeper and advance discovery in life science and translational research.

BTS Research is a Contract Research Laboratory that delivers cGMP/GLP biological services to clients in the pharmaceutical, biopharmaceutical, biotech, academic research, medical devices and related industries.

Buck Institute for Research on Aging is a biomedical research institute focused on studying the aging process and its effects on health.

Market opportunities created by evolving legislation legalizing recreational use of cannabis is generating a significant need for advances in rapid and accurate drug testing technology. Buzzkill Labs is developing next generation technology that will combine patented noninvasive sample collection methodology with scientifically validated laboratory detection and quantitation technology. Buzzkill Labs products will address the growing need for:SAFETY IN THE WORKPLACESUSPECTED IMPAIRED DRIVING BY LAW ENFORCEMENTFAST AND ACCURATE TESTING BY MEDICAL AND DRUG TREATMENT CENTERS

Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws. Alibrex is a blood-based assay, developed to help physicians identify patients who are not responding to drug therapy. The test is optimized to maximize NPV, that is, minimize the number of false non-responders.

Cairn Biosciences discovers new medicines by mapping multiscale cell dynamics. Our proprietary COMPASS™ discovery platform unlocks exclusive routes to novel targets and drugs by navigating uncharted, complex and dynamic disease biology. Using COMPASS, our diverse, multidisciplinary team of experts in drug discovery, disease biology, engineering and computation is pioneering a new drug discovery paradigm that utilizes our innovative simulations of living biology to deliver better therapeutics. We are initially orienting COMPASS to the exciting challenge of discovering new drugs that overcome acquired resistance to targeted cancer therapies. Cairn \​'kern\ a stone beacon marking the direction of a trail.

Cala kIQ is a healthcare technology company that specializes in digital therapeutics and medical devices.

CalChem Synthesis is a Contract Research Organization (CRO) serving as an outsourcing partner for the biotech and pharmaceutical companies and research institutions. The company mission is to provide high quality non-GMP chemistry services to the chemical community and to maintain customer satisfaction. Our services are based on the belief that our customers' needs are of the utmost importance and we are committed to meeting those needs. The experience of CalChem's team in synthetic organic chemistry and process research and development ensures that all projects are delivered with highest quality standards and on time. CalChem is located in the heart of "Pharma Corridor" in Torrey Pines, San Diego. Our leadership team has over 45 years of combined experience in different sectors of drug discovery and development in pharma industry. If you are located in Southern California, benefit from our services in your backyard and discuss progress of your projects in face-to-face meetings with our chemists on a weekly basis. For national and international clients, progress reports can easily be discussed by conference or video calls. We would welcome the opportunity to earn your trust and deliver you the best services in the industry. With our experience in pharmaceutical contract research and development, we ensure that your projects will be handled smoothly and in your best interest.

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.

Caldera Medical is a medical device company solely focused on women's health with a commitment to our mission of "Improving the Quality of Life for Women!" We develop, build and market best in class surgical products for the treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse. Working closely with surgeons to help those here at home, as well as women around the world, through our humanitarian programs to give them the access to the education and treatment they deserve. Mission - To Improve the Quality of Life for Women Vision - To be the Global Leader in Women's Pelvic Health Values "C4"​ - Care / Collaborate / Challenge / Create

Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

The California Animal Health and Food Safety Laboratory System (CAHFS) is the backbone of California's warning system that helps to protect the health of California's livestock and poultry. CAHFS serves the people of California by safeguarding the public health with rapid and reliable diagnoses for animal diseases including those affecting humans. CAHFS operates in partnership with the California Department of Food and Agriculture, UC Davis, veterinarians, and livestock and poultry producers. CAHFS provides quality services that protect animal health and performance, public health and the food supply.Located on the University of California, Davis campus, the Davis laboratory provides livestock, equine and avian necropsy, histopathology, immunohistochemistry, electron microscopy, toxicology, serology, microbiology and virology testing on site. Specialty services for equine performance chemistryand pharmacology are also located at the Davis facility.CAHFS Davis offers:American College of Veterinary Pathologists board certified diagnosticiansAmerican College of Veterinary Microbiologists board certified microbiologistAmerican Board of Veterinary Toxicology board certified toxicologistExperts in poultry/avian, horse, cattle, pig, llama, alpaca, sheep, goat, exotics and wildlife diseasesForeign animal disease trained diagnosticians on siteComprehensive reports which include gross examination, histopathology and testing in other disciplines as neededNational Poultry Improvement Plan approved site for Salmonella, Mycoplasma and Avian Influenza testing

Climate change, deforestation, forced labor and many other issues are putting the world's chocolate supply at risk of collapse. The time is now to build a cleaner and better future of food. We are developing the newest plant cell culturing technologies in order to create a new supply of chocolate that is scalable, sustainable and better for the planet.

California Department of Fish and Wildlife's mission:To manage California's diverse fish, wildlife, and plant resources, and the habitats upon which they depend, for their ecological values and for their use and enjoyment by the public.

California Institute of Technology - Caltech is an educational and research institution that focuses on science, technology, and engineering.

CenExel is a leading integrated, wholly owned, nationwide clinical research site network comprised of 18 Centers of Excellence in major metropolitan areas across the U. S. With 40+ years of experience, our Centers of Excellence deliver deep scientific expertise, premium data, operational efficiencies, and exceptional patient engagement to drive successful complex clinical trial outcomes. The world's most results-driven Pharma, Biotech, and Clinical Research Organizations trust our strategic approach and benefit from our collaboration and unified sites' commitment to real world solutions. Rely on us to confidently progress from site selection to study close-out and accelerate life-changing therapies. Get more value from your clinical trials with CenExel.

California State University, Fullerton is a public university in Fullerton, California. With a total enrollment of about 40,400, it has the largest student body of the 23-campus California State University

Founded in 1901, California Polytechnic State University (Cal Poly) is one of five comprehensive polytechnic universities in the U.S., with about 18,000 undergraduate and 900 graduate students. Located in San Luis Obispo, 200 miles north of Los Angeles, Cal Poly maintains a guiding philosophy of “Learn By Doing” that is reflected in the school’s comprehensive curriculum combining technical and professional training with the arts and humanities. When you graduate from Cal Poly, you won’t just know theory you will be able to think critically and know how to solve real-world problems. Today, Cal Poly is among the most selective public universities in the United States. Under President Armstrong’s leadership, Cal Poly’s national reputation is growing and, according to payscale.com, the return on investment for graduating students is consistently on a par with some of the most prestigious universities in California. Visit www.calpoly.edu to learn more. For Cal Poly Jobs, Visit: http://ow.ly/THgQc Awards & Recognition in 2014: - #1 Public-Master's University in the West by U.S. News. 22 consecutive years - #70 out of 1,500 colleges for "best overall value"​ - #13 among public schools for graduates'​ median salaries - #7 among public universities for return on investment - #4 in the nation for Aerospace & Computer Engineering - #5 in the nation for ROI, Orfalea College of Business - #1 in the nation for Industrial/Manufacturing Engineering - #3 in the nation for Civil Engineering - #1 in the nation for Architecture and Design - #4 Aerospace Engineering program in the nation for universities that do not offer a doctorate - Top 10 colleges for highest paid graduates in the field of Education

Calysta is a world leader in cellular agriculture, creating protein without limits via a patented fermentation platform that uses no arable land, plant or animal products. As the world's demand for healthy, sustainably produced food continues to grow, Calysta's family of ingredients – FeedKind, FeedKind Net Zero, and Positive Protein – are ready to meet the challenge. Powered by renewable energy, Calysta's protein products can preserve biodiversity and contribute to improving the global nexus of water, energy and food security.

Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones, a common and painful condition that consumes vast amounts of healthcare resources today. Founded in 2016, Calyxo is led by executives and investors with a strong track record of commercializing paradigm-shifting solutions in the field of urology. Our team features some of the most talented, high-achieving and brightest minds in the medical device industry who are compelled by a desire to make a difference in kidney stone care. We are proud of our collaborative, diverse, fun and dynamic culture. We drive our actions based on our core values which we call ‘F.I.T to WIN.’ Find Joy: We celebrate wins and enjoy the journey! Integrity: We are truthful, honorable, and reliable. Transparency: We share what’s going on in our business. We are open, honest and have a clear communication across our organization. Win as a Team: We are earnest collaborators. We hold ourselves and each other accountable.

Welcome to the Cancer Center of Southern California. Contact us today to schedule an appointment with a leading oncology expert in Los Angeles!

CancerVAX is a drug development company focused on developing novel therapeutics in the oncology space. In partnership with the UCLA School of Medicine, we are progressing two programs: 1) Ewing sarcoma; 2) Universal cancer vaccine. CancerVAX is privately funded

Developing innovative therapeutics to materially improve the lives of patients. We strive to be transparent and open in our goals, plans, and progress.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Cannuflow is a healthcare technology company that offers innovative fluid management solutions for knee, shoulder, and hip arthroscopy procedures.

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.

Cantata Bio is enabling researchers and clinicians to solve tomorrow’s most challenging scientific problems through novel, multiomic approaches that unlock access to genomic and metagenomic information at unprecedented levels. Combining propriety technologies with platform solutions, services, and cutting-edge bioinformatics and software, our unique approaches are solving complex problems, including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing, metagenomics, and microbiome analysis. Our customers are positively impacting the fields of epigenetics, developmental biology, cancer research, evolutionary biology, infectious disease, and more. Cantata Bio is based in Scotts Valley, California and Cambridge, Massachusetts. For more information on Cantata Bio, its technology, and offerings, visit www.cantatabio.com.

Embracing Innovation: Transforming Hyperbilirubinemia Management with CoSense ETCOc Technology. The CoSense® ETCOc Monitor performs a non-invasive, bedside breath test using a nasal cannula, and identifies hemolysis and neurotoxic risks from rising unconjugated bilirubin, aiming to prevent hemolytic HB and Kernicterus. Grounded in extensive research, peer-reviewed studies, and neonatology expert endorsements, CoSense® revolutionizes neonatal care by enabling precise, customized interventions, including vigilant monitoring and effective phototherapy, setting new care standards in neonatology.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.

CapsoVision is a medical device manufacturer based in Silicon Valley, USA. We are engaged in the development of innovative capsule endoscopy (CE) solutions that empower physicians, streamline clinical operations and enhance patient experience. Our novel small bowel capsule endoscope CapsoCam Plus® is the only CE system with a 360° field of view, no capital equipment, and a state-of-the-art CapsoCloud® cloud-based software for efficient image review and analysis.

At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.

Caption Health has been acquired by GE HealthCare. Follow us at @GEHealthCare and @CaptionCare for the latest updates and healthcare news.

Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and Cardiff's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

At Caresyntax, we are dedicated to making surgery safer and smarter. Our mission is to converge AI-powered software, devices, and clinical services to help our customers improve surgical outcomes. Our platform, an enterprise-grade surgical intelligence system, is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. The platform generates insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery. Headquartered in the US in San Francisco and internationally in Berlin, Caresyntax software is used in over 3,000 ORs globally and aids surgical teams in over 3 million procedures annually. To learn more about how we're transforming surgical care, visit us at www.caresyntax.com.

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Drug discovery and development to target the root causes that drive cancer and metabolic diseases using Chemotype Evolution.

Building a smarter roadmap for precision therapeutics.

We are an ISO 13485:2016 Certified Manufacturer developing innovative media formulations for cell cryopreservation, cell culture, and cell handling in cell therapy, gene therapy, and regenerative medicine. We deliver high-quality products with batch-to-batch consistency and rigorous quality controls from raw materials to final product release. We offer manufacturing services, scientific assistance in media formulation, and optimization of existing formulations to meet your specific needs.

CB Therapeutics is an innovative producer of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics' expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms. CB Therapeutics is focused on the discovery, research, development and production of tryptamines, cannabinoids and other molecules and compounds to advance Neuroscience and bring therapeutics to market to solve mankind's most challenging mental healthcare and social problems.

• The Cedars-Sinai Biomanufacturing Center (CBC) is a new 25,000 square feet, state-of-the-art biomanufacturing facility located in West Hollywood, California. • Manufacturing the next generation of cell and gene therapies for human IND-enabling clinical trials. • cGMP cell manufacturing facility housing multiple cleanroom cell production suites and process development laboratories. • Combined expertise in a cGMP-compliant approach to manufacture cells at scale with innovative technologies and equipment. • Transferring laboratory protocols to cGMP, up-scaling of processes and achieving Food and Drug Administration standards to bring innovative cell therapy solutions to researchers and translational scientists. • World-class expertise in stem cell (iPSC) biology, gene editing and bioprocessing. • Supporting California Institute for Regenerative Medicine (CIRMN) programs, CBC is providing a much-needed cell biomanufacturing center in California

Cel Analytical Inc. (Cel-A) is a certified environmental laboratory offering full service chemistry, microbiology, and molecular biology testing for environmental samples. Cel-A is located in downtown San Francisco and is proud to work with clients from all sectors, including federal and state agencies, local municipalities, environmental consulting firms, construction companies, and homeowners.

CeleCor Therapeutics - We’re a biotechnology company on a mission to develop therapies that will get patients with a heart attack to the hospital with open coronary arteries. We focus on developing pre-hospital therapies, because early action is crucial to preserve heart muscle. The longer a coronary artery is closed, the more severe the damage to the heart. Starting treatment before patients reach the hospital, significantly improves the chances of a positive outcome. We’re developing zalunfiban; a prompt, potent, and predictable medication designed for treating patients with a heart attack before they reach the hospital. Zalunfiban has the potential to fulfil a significant unmet medical need in the pre-hospital phase of heart attack care. We’re currently running the CeleBrate trial: a pivotal Phase 3 prospective, blinded, randomized, placebo-controlled, international, multicenter, study designed to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in patients with ST-segment elevation myocardial infarction in the pre-hospital setting.

Celemics is a Next Generation Sequencing (NGS) full solution provider based on target enrichment technology. We confidently offer custom target enrichment panels and high-quality pre-set panels, covering fields such as Inherited Diseases, Oncology, Immunology, and Pathogen Diagnostics. With 13 years of experience, we will provide the best solution for your Targeted Sequencing. [Products/Services] OncoRisk (Hereditary Cancer) | CancerScreen (Somatic Cancer) | Custom Target Enrichment Panel | Whole Exome Sequencing | Clinical Exome Sequencing | BRCA 1/2 | PharmacoScreen | Comprehensive Respiratory Virus | Agrigenomics

Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious diseases, rare diseases and cancers.

Cellana, a leading developer of algae-based bioproducts, uses the most productive plants on earth—marine microalgae—to photosynthetically produce its ReNew™ line of Omega-3 EPA and DHA oils, animal feed, and biofuel feedstocks. Cellana's mission is to develop and operate highly profitable commercial scale algae biorefineries and to establish Cellana as a leading source of algae-based products serving the human nutrition (Omega-3), animal nutrition, and biofuel markets.

Global Leadership in Primary Cells: Excellence in cell isolation, 3D bioprinting, tissue engineering, 3D cell models, stem cells, optimized culture media and more. CAI's products and custom services support basic life science research and biopharmaceutical drug discovery. Our Center for Primary Cell Innovation pushes the edges of technology, with regular advancements developed in collaboration with academic & industry experts.

Cellastra Inc., a developer of disruptive gene therapies, is a private biotech company based in the San Francisco Financial District. It was founded and managed by proven industry executives with a track record of execution. Cellastra’s mission is to develop Disruptive, First or Best in Class Gene Therapies. Cellastra Proprietary Technology - Gene Vector- Anti-scarring peptide: Cellastra is developing viral gene vector-mediated intervention to address an area of great unmet medical needs in scarless wound healing after surgery and respiratory infections: 1. Surgery: Prevent excessive dermal scarring, e.g., after breast augmentation surgery, and C section. 2. Respiratory Infections: Prevent an excessive immune response, tissue damage, and scarring/fibrosis in high-risk patient groups with respiratory infections such as COVID-19 (coronavirus disease 2019) and RSV (respiratory syncytial virus). Scarless wound healing can be achieved by using a gene vector encoding for endogenous continuous production of the anti-scarring peptides at the site of injury. Thus, two gene vectors are planned for development (Cellexa applied under the skin after surgery and Virexa inhaled into the lungs in COVID-19 and other respiratory infections). The development of these vectors is built and expands upon a foundation of scientific proof of concept data of the anti-scarring peptide ensereptide.

Cell Biolabs, Inc. proudly develops and commercializes innovative technologies and tools for life science research. We are committed to providing the best products that facilitate discovery of the mechanisms underlying cell function and disease. Our unique, cutting-edge products are currently used around the world in the research laboratories of universities, government institutes, biotechnology and pharmaceutical companies

Cell Care Therapeutics is developing a new class of biologics that are derived from the secreted proteins and exosomes of mesenchymal stromal cells (MSCs). The company’s novel secretome platform harnesses the signaling molecules of MSCs to promote the health of blood vessels and their surrounding tissue. The company is developing its first product for the treatment of diabetic macular edema, the leading cause of vision loss in working age adults.

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

Cellevolve - Cell therapies are revolutionizing the treatment of disease and are poised to transform health outcomes. Advances in biology and technology have enabled the development of innovation in a more distributed way than ever before: there is a wave of novel therapeutics in academic centers and biotechs around the world looking for partners to advance their inventions. That’s where we come in. Our approach is to bring clinical stage therapies through late stage development and commercialization by partnering with innovators at academic medical centers and small biotechs around the world.

CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology: • Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells. • Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

CellMax Life is a leading cancer diagnostics company whose mission is to transform how cancer is diagnosed and managed with globally affordable non-invasive tests for early cancer detection and management. CellMax's unique expertise in both Circulating Tumor Cell and Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA) has enabled multiple highly effective precision medicine solutions for healthy people as well as patients diagnosed with cancer.

CellSight Technologies is a privately held molecular imaging company. Our mission is to discover, develop and commercialize PET (Positron Emission Tomography) imaging companion diagnostics for the development of therapies and the clinical management of patients. CellSight was recently granted eIND approval for a novel probe to visualize activated T cells. [18F]F-AraG is a substrate for enzymes naturally over-expressed inside activated T cells which allows us to image the level of expression in living subjects with no alteration of the T cells. Imagine being able to provide an immuno-oncology patient with efficacy information within days versus the months required with current practices. CellSight also has eIND approval on a reporter gene / PET probe combination that allows repeated imaging or engineered cells. The GSV1-tk reporter gene in conjunction with the [18F]FHBG PET probe has been used clinically to monitor therapeutic cell migration, proliferation and survival. I invite you to visit our website for additional information: www.cellsighttech.com

Celula is a biotechnology company that offers Celula IDA, Integrated Diagnostic Accuracy, providing better solutions for prenatal testing and novel approaches to cancer detection.

Cenna Biosciences is revolutionizing Alzheimer's treatment with proprietary small peptides and molecules that inhibit beta amyloid production. The company is focused on developing disease-modifying drugs for Alzheimer's disease using a proprietary novel mechanism.

Centivax’s mission is to accelerate the world’s transition to a post-pathogen humanity.

Centrillion Tech’ mission is to empower researchers, physicians and consumers to have responsible and cost effective access to genomic information and to advance personalized health care, molecular diagnostics and individualized wellness management. Founded in 2009, Centrillion Biosciences'​ research and product development operation is focused on novel bridging technologies that solve critical problems in large-scale genomic analyses (including sequencing) and informatics. Our service operation has provided high-quality genomic services and has been well received by academic and industrial customers

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com. Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Cercle is an AI technology company with the mission to advance healthcare for all women. With AI, we harness anonymized, diverse and reliable biomedical and genomics data from around the world to deliver unprecedented and secure healthcare insights. The Cercle™ Biomedical Graph is a first-of-its-kind knowledge graph. It uses AI to analyze billions of anonymized data points securely drawn from hospitals, clinics and research labs from all over the globe. We're turning raw, unstructured and disconnected biomedical and genomics data into clear insights for doctors, hospitals, research centers, pharmaceutical companies, labs and clinics so they can treat patients more effectively. That's how we support innovation and advancements in treatments and healthcare outcomes across the entire healthcare ecosystem. Women's health is the most underserved healthcare market, which is why Cercle's first focus will be fertility and IVF. We're proud to beta launch Luce, a fertility companion for women and doctors that analyzes data from thousands of treatment cycles to help people make more informed decisions for their fertility journeys. Cercle's suite of products includes: — Data access tools: Researchers and lab directors can query and visualize structured biomedical and genomics data to accelerate health innovation. — Modeling and insights products: Advanced modeling tools help healthcare providers with financial and operational strategies. — Tools for clinicians: Doctors get personalized care insights and predictive treatment outcomes based on Real World Data and Real World Evidence. — Patient companions: Patients get clear, data-driven insights that make it easier to understand their health and make informed decisions with their doctors. Cercle is built by medical professionals, molecular biologists, data scientists, engineers and business entrepreneurs dedicated to unlocking a world where everyone feels informed, empowered, and in control of their own health.

At CERo, we are expanding the armamentarium of engineered cell therapies to create a whole new class of innovative medicines for oncology. Armed with an understanding of cellular clearance and molecular immunology, we engineer cells to engage new and complementary cell elimination pathways to enable deeper and more sustained clinical responses to maximize wellness.

Certis Oncology is a life science technology company committed to realizing the promise of precision oncology. Certis was founded in 2016 with a singular purpose: to bring certainty to the fight against cancer. Their science delivers clinically relevant, predictive data and they are located in the heart of San Diego's Life Sciences center, Sorrento Valley.

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Resident company JLabs San Diego focused on the development of immunotherapy for substance abuse.

CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.

Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.

Channel Medystems develops a cryotherapy device for the treatment of gynecology disorders.

The Chan Zuckerberg Biohub Network is a group of nonprofit research institutes that bring together scientists, engineers, and physicians with the goal of pursuing grand scientific challenges on 10- to 15-year time horizons. The CZ Biohub Network focuses on understanding underlying mechanisms of disease and developing new technologies that will lead to actionable diagnostics and effective therapies. CZ Biohub San Francisco — which was the inaugural Biohub and launched in 2016 — works on elucidating dynamic cell systems across scales in health and disease, joining forces with the Bay Area’s leading academic institutions — Stanford University, UC Berkeley, and UC San Francisco — to do bold, visionary science that can’t be done elsewhere. CZ Biohub Chicago, which launched in 2023, focuses on engineering technologies to make precise, molecular-level measurements of biological processes within human tissues, with an ultimate goal of understanding and treating the inflammatory states that underlie many diseases. It catalyzes collaboration between the University of Chicago, Northwestern University, and the University of Illinois Urbana-Champaign. CZ Biohub New York, which launched in 2023, brings together Columbia University, The Rockefeller University, and Yale University to bioengineer immune cells to sense and record signals of disease and adapt these cells to spot diseases such as lethal cancers and Alzheimer’s in their earliest stages, long before they are usually diagnosed.

The mission of Chapman University is to provide personalized education of distinction that leads to inquiring, ethical, and productive lives as global citizens. Consistently ranked among the top universities in the West, Chapman University provides a uniquely personalized and interdisciplinary educational experience to highly qualified students. Our programs encourage innovation, creativity, collaboration and focus on developing global citizen-leaders who are distinctively prepared to improve their community and world.

Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.

Checkerspot engineers microalgae to produce new molecular building blocks and applies chemistry tocreatematerials with novel physical properties.Checkerspot has a consumer brand, WNDR Alpine that makes skis, using foam and other materials from algae. The company is also making performance textiles.

ChemBridge Corporation is a global provider of enabling chemistry products and contract research services for small molecule drug discovery and chemical biology research. ChemBridge's extensive portfolio includes over 1.3 million diverse and target-focused screening compounds, 14,000 chemical building blocks, 10,000 synthetic macrocycles, our Hit2Lead.com on-line chemical store, and high-end, research-intensive custom library and synthetic/medicinal chemistry services. ChemBridge's research products and services are supported by an experienced, dedicated and friendly customer service and project management team at our San Diego headquarters and by ChemBridge's 25-year track record of innovation, quality and deliverability.

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA. ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital. - 25 years experience and 2500 customers worldwide - Premium R&D CRO based in USA with global reach - Seasoned project managers - Extensive Academic partnerships - Flexible business models - Competitive pricing options - Industry's largest ever-greening stock compound inventory - Ongoing investments in novel proprietary chemistry and discovery platforms One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners. #pharma #biotech #chemistry #screening_Libraries #drug_discovery_services

For more than a century, some of the world’s most significant energy innovations have been developed here in Richmond at Chevron's Richmond Technology Center (RTC), a unique research and development facility located adjacent to the Refinery.The team of scientists in Richmond are continually focused on delivering a competitive advantage to business partners through technology.

Founded in 2017 and based in the San Francisco Bay Area, Chi Botanic is a plant cellular agriculture company focused on how natural products are made through plant stem cell cultures.

Chimera's mission is to reprogram life to end cancer, using therapies that restore dignity to patients. We do this with next generation, safer and more potent, CAR T therapeutics.

CHO Plus is creating regulatory compliant genetically engineered mammalian cells to be used by biopharmaceutical companies for therapeutic protein manufacturing. Early proof of concept experiments demonstrate CHO Plus cells to be 4.5-fold more productive than parent cells in model system. The CHO Plus approach includes patented methods for genetically engineering mammalian cells; proprietary and patented targeted transfection technology; and efficient clone screening technology.

ChromaCode is deploying a solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​.COVID-19: EUA (06/2020) for its HDPCR SARS-CoV-2 Real-Time PCR

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. NIAGEN NR is the active ingredient in ChromaDex's consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States*. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex's robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information. *Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform.

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. They recently raised Series B and Series C financing from The Column Group and NextTech Invest. Circle Pharma design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. They do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). They have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Circle Pharma workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. They deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

Cirsium Biosciences is democratizing gene therapy through transformative viral vector production methods and systems.

Citrine empowers product experts with vanguard AI technologies. With no background in data science, product experts apply Citrine to deliver next generation products faster than any other time in history. Citrine’s software learns easily from the knowledge of its users and their idiosyncratic data to enhance all aspects of the product lifecycle across all industries with a physical product. Citrine’s users increase supply chain efficiency, rapidly improve product quality, enhance customer experience, expand product reach and increase the velocity of product delivery. With Citrine, product experts unlock the capability to solve our society’s greatest environmental and productivity challenges. Citrine's customers include Eastman, Panasonic, Grace, LyondellBasell, LANXESS, Morrow Batteries and some of the biggest and most respected names in the materials and chemicals and CPG industries in Asia, North America, and Europe. For more information visit our website at https://citrine.io.

We are excited to announce that Clara Health has been acquired by M&B Sciences, a mission-aligned and strategic partner in the clinical research space. We strongly believe that by merging with M&B, we are able to make a greater difference in how patients experience clinical trials and contribute to breakthrough research.

Claremont BioSolutions is a privately held, emerging growth technology company specializing in miniaturized, disposable devices that provide solutions to what is recognized as the "bottleneck" of DNA diagnostics – sample preparation. The company has developed proprietary disposable devices which employ micro-motors to perform very efficient mechanical tissue homogenization, cell lysis, and nucleic acid purification. Their efforts toward solving sample prep challenges with hard to handle sample matrices and pathogens have led the company to its development of unique reagents and buffers that are of broad interest in the diagnostics industry.

We are an early-stage biotech startup based in Santa Cruz. We are a small, motivated, multi-disciplinary team innovating in NGS sequencing technologies and DNA assay design for applications in molecular diagnostics with focus on liquid biopsies, FFPE and ancient DNA Interested in beta testing our single-stranded approach to NGS library prep? Get in touch! www.claretbio.com/contact We are always looking to build our team with seasoned scientists who want to be on the ground-level of ground-breaking technology.

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

ClearFlow, Inc. is a medical device company that specializes in innovative surgical drainage solutions. Founded in 2007 by cardiothoracic surgeons Dr. Edward Boyle and Dr. Marc Gillinov, the company focuses on improving outcomes in cardiac surgery by addressing complications related to retained blood and fluids after surgery. The company's primary offering is the PleuraFlow Active Tube Clearance System, a chest tube designed with Active Clearance Technology (ACT). This system helps maintain patency and prevent occlusions, reducing the risk of "failure to drain" events that can lead to longer hospital stays and increased costs. ClearFlow's products are targeted at hospitals and healthcare facilities performing cardiothoracic surgeries, particularly in intensive care units. Led by President and CEO Paul Molloy, ClearFlow is committed to developing devices that enhance patient recovery and reduce healthcare costs. The company has received FDA 510(k) clearance and the CE Mark for its PleuraFlow system, reflecting its dedication to providing reliable solutions for clinicians.

Invitae, now part of Labcorp, is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We're working to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of our mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Within each of us lies information coded in our DNA that can transform our health. Unlocking that potential requires highly specialized, multidisciplinary collaboration. Our world-class genetics experts drive the development of a highly complex system of tools and processes, including robotics, artificial intelligence, machine learning, and software engineering. All of this comes together to provide patients with accurate, reliable results that can help guide decisions across the healthcare journey and potentially change lives today and for the next generation. Our teammates are grounded in a universal sense of urgency and ownership. We believe in the team above the individual and celebrate freedom with accountability. Employees are encouraged to speak up, try new things and make decisions that push us forward. We provide all Invitaens with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. At Invitae, we're putting patients' genetic insights where they belong—at the center of healthcare. And we're doing it together, with you. Join us.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

A surgical device company dedicated to cutting costs, prioritizing patients, and simplifying surgery.

bio-analytical services

We're a dedicated team of engineers, data scientists, doctors, innovators, and creative thinkers from across the globe. We're united in our drive to use technology to simplify healthcare and make it work better for everyone involved. We unify all data sources and other systems together for a complete picture. We automate for efficiency throughout. Clinical, operations, and financial results are collected and coordinated like never before.

Coagulant Therapeutics seeks to address acute bleeding, a significant area of unmet medical need and includes the indications post partum hemorrhage, intracranial hemorrhage, traumatic brain injury and blunt trauma.

Coagulation monitor

Coastar Therapeutics is a pre-clinical biotech company developing biological payload delivery technologies for cancer immunotherapy and gene therapies. Our proprietary ENHEnS technology can be used to coat biological payloads with cell membranes, which help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites.

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Cognoa innovates solutions for child developmental health. We build breakthrough products like Canvas Dx, the first and only FDA authorized autism diagnostic for children ages 1.5 to 6 years that uses responsible AI to empower doctors to quickly, accurately, and fairly diagnose developmental risk without bias. Our digital solutions are child centric and designed to find, assess, and treat developmental concerns early, within the time windows that will yield the optimal outcomes. Our proprietary "whole child" approach to AI fuels our pipeline of diagnostic and therapeutic products for autism, speech and language, ADHD, childhood anxiety, and more. For more information, visit www.cognoa.com.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

Colby Pharmaceutical Company is developing drugs for inflammatory conditions.

Collaborative Drug Discovery's CDD VAULT is a hosted biological and chemical database that securely manages your private and external data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy-to-use web interface. The available modules within CDD Vault include Activity, Registration, Visualization, Assays, AI, Automation, Curves, Inventory, and Electronic Lab Notebook (ELN). Each module is designed to optimize various aspects of research and data management, enhancing the overall efficiency and productivity of scientific workflows. CDD Vault is a system your entire team can actually use! Engineered for Ease of Use CDD Vault allows you to enjoy the benefits of large enterprise systems without the administrative burden or expense. Modern Cloud Solution Saves Money CDD Vault is affordable to academic laboratories, research foundations, and small companies. Beats Juggling Spreadsheets of Screening Data! Eliminates the Risk of Data Loss CDD Vault provides a secure environment to collect all your compound and screening data. Get Better Results from Unified Data CDD Vault consolidates all your compound and screening data in one place. This makes analysis easier, more consistent, yielding results more quickly. Securely Store Experimental Data in a Private Hosted Vault Data Migration is a Snap CDD Vault can provide easier access and better management of your existing data too. Safely Share Data CDD Vault allows you to selectively share data in real time with your designated researchers in your own lab or across the globe. Security is Built-In - CDD Vault is protected with SSAE 16 Type II certified cloud storage on locked and guarded hardware. https://www.collaborativedrug.com/pages/benefits CDD VAULT from Collaborative Drug Discovery https://www.collaborativedrug.com

Collaborative Medicinal Development LLC is a company based out of 184 Bulkley Avenue, Sausalito, California, United States.

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

CompactCath is a medical device company committed to improving the quality of life for self-catheterizing patients, their families, and healthcare providers. Designed and founded at Stanford University by a team of physicians, engineers, and catheter users, we are driven by a goal to design medical devices that enable those with chronic conditions to lead active, thriving, independent lives. CompactCath, our flagship intermittent urinary catheter, is a revolutionary pre-lubricated, non-touch catheter for users looking for a compact, discreet, and easy to use solution that fits seamlessly in their lives. CompactCath is FDA cleared in the US and CE approved in Europe. For more information, visit our website: www.compactcath.com and watch our video: https://www.youtube.com/watch?v=k8cjjgfGhAY

Comparative Biosciences Inc., a Genesis Drug Discovery and Development (GD3) Company, a premier preclinical contract research organization (CRO) committed, for the last 20 years, to providing expert high-quality contract research services to all sectors of the biomedical community. Extensive experience in the biotechnology and pharmaceutical industries provides our staff with an exceptional track record in preclinical research and drug development capabilities. Our on-site histology laboratory offers routine histopathology, special stains, immunohistochemistry (IHC), plastics, GLP antibody tissue cross reactivity (TCR), and histomorphometry services with quick turn around times. We also have the benefit of having an on site board-certified pathologist for evaluation and reporting of all the histology work done here.

Working on turning stem cells into human eggs

Confidence Pharmaceutical Research (CPR) is a dynamic force in the pharmaceutical industry, driven by a vision to revolutionize drug development. With a dedicated team of over 100 passionate professionals, Confidence combines the global reach and full-service capabilities of a large Contract Research Organization (CRO) with the agility and client-centric focus of a boutique firm. Our lean management approach ensures cost-effectiveness without compromising on quality, making us an ideal partner for organizations seeking innovative solutions in drug discovery and clinical research.

ConfometRx is a leader in G protein coupled receptor (GPCR) structural characterization and analysis and GPCR-targeted drug discovery.

ConKay Medical Systems is an early-stage medical device company advancing unique solutions to treat valvular regurgitation in patients with progressive heart failure. Valvular regurgitation is when your valves do not close properly allowing blood to flow backwards in your heart causing shortness of breath, chest pain, and sometimes death. There are over 100 million people currently affected globally with valvular disease and an additional 5M Americans are diagnosed each year. ConKay's annular repair technology is designed to treat the main cause of functional regurgitation leaving the healthy leaflets intact to perform the way it was intended. We are currently focused on the Tricuspid valve. Message us for more information!

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company’s lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum targets biological pathways associated with specific clinical disabilities, that once modulated, can demonstrably impact the course of disease.

CONTRACT PHARMA is the multi media information outlet dedicated to bio/pharma outsourcing. From drug development to manufacturing, we cover the latest developments, views and opinions from industry leaders in print and online. CONTRACT PHARMA offers advertising opportunities in our print magazine, Contract Pharma Direct weekly e newsletter and on contractpharma.com. We are the only worldwide print publication focused on Bio/Pharma contract services, delivering a total qualified circulation of 20,013. (VAC audit statement) On Sept. 26-27, 2024 CONTRACT PHARMA will host its 23rd Annual Contracting & Outsourcing Conference & Tabletop Exhibition. This event brings together speakers from the FDA, industry leaders, and expert analysts to discuss issues critical to success for Pharma & Biopharma outsourcing. The one-day Tabletop Exhibition of 160 top contract service providers provides great exposure to outsourcing decision makers. CONTRACT PHARMA's Corporate Capabilities and Contract Services Directory is the largest single source for company profiles and contract services. This standalone print issue showcases the services of Bio/Pharma contract service providers. The Contract Services Directory is also available online at www.contractpharma.com/csd. It's an indispensable guide for contract services in print and online. Every week, thousands of Bio/Pharma outsourcing professionals go to www.contractpharma.com to read current features, find archive stories, and get breaking news and online exclusives. We also e-mail CONTRACT PHARMA DIRECT, our weekly e-newsletter, to more than 20,000 people. CPDirect is filled with the latest news, our most recent articles, and links to our popular annual features and upcoming meetings. Free subscriptions are available on our website. Contact us for more information on how your company can get involved with Contract Pharma.

Conversio Health is an innovative chronic condition management company focused on COPD and Asthma Disease Management. They aim to improve outcomes, prevent hospitalizations, and reduce the total cost of care for chronic respiratory conditions.

We’ve been unlocking the potential of cortisol modulation for more than 25 years. We’re leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.

Core Diagnostics is a California licensed CLIA certifiedlaboratory offering biomarker analysis and translational research support for studies ranging from early discovery to analyses of Phase III clinical trial samples.

The Cornea Biosciences biosynthetic replacement corneal will help reduce world corneal blindness. More than 15 years of research have gone into development of the Company's cornea. It will provide a safe, affordable, biocompatible cornea for the millions of people unable to obtain corneal transplants due to a severe shortage of human corneas.

Correlia Biosystems develops innovative microscale tools that accelerate the rate of molecular interactions for rapid measurements of biomolecules. The customizable PIXI​ platform opens up new biological questions for interrogation from less than two microliters of sample, with rapid results that allow for dynamic monitoring of protein expression profiles.

Cortechs.ai develops and markets cutting-edge imaging solutions that are used by radiologists, neurologists, and oncologists in hundreds of clinics and research centers around the world. The Cortechs.ai team includes scientists, engineers, business professionals, and clinical specialists working towards the common goal of improving the diagnosis and treatment of patients with neurodegenerative disorders and cancers. Cortechs.ai's​ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.

Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology. The OptiMap™ System is a 510k cleared, electrographic flow mapping solution designed with AI, enabling physicians to See What Matters.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial.

Diagnostics

Founded in 2001, we are the third largest peptide-focused contract research, development, and manufacturing organization (“CRDMO”) worldwide in terms of sales revenue in 2023, according to Frost & Sullivan. We are also considered one of the most comprehensive peptide-focused CRDMO globally (Frost & Sullivan), offering complete life-cycle support from early-discovery, pre-clinical research and clinical development to commercial production. We mainly provide (i) contract research organization (“CRO”) services, including peptide new chemical entity (“NCE”) discovery synthesis; (ii) contract development and manufacturing organization (“CDMO”) services, including peptide chemistry, manufacturing, and controls (“CMC”) development; and (iii) contract manufacturing organization (“CMO”) services, including peptide NCE and generic drug commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets in the United States, China, Japan, Europe, South Korea, and Australia. We also provide customers wit peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide. In addition to peptides, we have developed a diverse project pipeline focusing on various types of complex peptide- and oligonucleotide-based new chemical entities (“NCEs”). Our peptide conjugation services seamlessly integrate our peptide and oligonucleotide platforms to produce a wide range peptide conjugates products. The introduction of our PeptiConjuXTM and PeptiNuclide LinkTechTM are dedicated to the development and large-scale manufacturing (i.e., kilogram-scale) of peptide-oligonucleotide conjugates (“POC”), peptide drug conjugates (“PDC”), and radionuclide drug conjugates (“RDC”). As of December 31, 2023, we had successfully synthesized approximately 1,800 molecules through these two platforms.

Sutter Health is one of the nation's leading not-for-profit healthcare systems, which includes award-winning physician organizations, acute care hospitals, surgery centers, medical research facilities and specialty services. Our team of 68,000 doctors, employees and volunteers proudly cares for Northern California. Our facilities and care centers are located in large, urban cities and small, rural communities, from the Pacific Coast to the San Joaquin Valley. You'll find us in San Francisco, Oakland, Sacramento, the snowy mountains of the Sierra Nevada and Lake Tahoe, Napa Valley, Yosemite and the coastal redwoods. We even have an affiliate in Hawaii. Join us and be part of a dedicated group of professionals committed to putting patients' needs first and achieving the highest levels of quality, access and affordability.

Credence MedSystems is setting a new standard in drug delivery, helping drug manufacturers differentiate their products through innovative delivery systems while preserving trusted processes. Credence is an innovator in injectable drug delivery devices, offering our pharma partners a simplified path to commercialization of a best-in-class delivery system. The Companion Safety Syringe System was born from Credence's philosophy of Innovation Without Change, allowing our customers to impress and protect their end users while preserving their existing processes, sourcing strategies and preferred primary package components. The Companion is available in luer needle, staked needle and dual chamber reconstitution configurations. Across the platform, the user performs the injection, receives end-of-dose cues and then the needle automatically retracts into the syringe, preventing reuse.

Reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Here at CRISPR QC, we empower scientists using CRISPR to solve the world's great challenges by providing the key cornerstones of information and insight fundamental to realizing the full potential of CRISPR.

Cruz Foam is a materials technology company that's working to catalyze the global transition from single use plastics to all natural, renewable materials. We strive for global adoption of circular solutions without compromise. For more information visit www.cruzfoam.com.

CTK Biotech is a biotechnology company that specializes in medical diagnostics for healthcare applications.

We are building a new company to transform the cell therapy space by developing autologous cell therapies for patients with solid tumors. We are building a company culture based on collaboration, transparency, integrity, and commitment to excellence. We are looking for passionate people to be a part of this journey.

Culture is your bioreactor lab, in the cloud. We help scientists accelerate bioprocess development with our high-throughput bioreactor cloud lab. You design your experiment, and we execute the experiment in our lab using our 250mL bioreactors. We take care of the high-quality execution so that you can focus on developing processes. While your experiment runs in our lab, you can monitor and analyze your data in real time using our online dashboard. With Culture, get faster insights to make better, data-driven decisions.

Cureline is a global precision and translational medicine CRO located in California (USA). With more than a hundred validated clinical partners in 20 countries, HBS repository in San Francisco Bay area and excellence in laboratory services, Cureline provides a full spectrum of translational research services: global regulatory affairs, custom protocol HBS biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2003 Cureline is a global leader in commercial biobanking and biomedical research services with a focus on targeted drug R&D, biomarker research and companion diagnostics development.

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

CURE Pharmaceutical is an innovative drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. Our mission is to improve people's lives by redefining how medicines are delivered and experienced.

Developing simple to use technology to understand complex cellular biology. We are a team of scientists passionate about genomic technologies and how innovative technologies fuel new waves of scientific discoveries and clinical applications. Our group consists of reputable inventors in both academia and industry, as well as seasoned biotech entrepreneurs and executives with a strong track record in bringing genomic technologies from concept to commercialization.

CURx Pharmaceuticals is a pharmaceutical company specializing in clinical and commercial development of therapeutics addressing unmet medical needs in patients with chronic disease.

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Cypre is a biotechnology company dedicated to working with therapeutic innovators to overcome drug resistance for cancer patients. Used by top-10 pharmaceuticals, a multitude of biotechs, and leading academic centers, our 3D in vitro tumor microenvironment models are currently offered as a joint service with Charles River to rapidly screen and generate novel insights into your therapeutic's efficacy and mechanism of action.

Cytek® Biosciences Inc. is a leading manufacturer and supplier of flow cytometry products and services. Cytek’s compact, affordable instruments and wide ranging support offerings are used by researchers and clinicians all over the world. Flow cytometry is a powerful analytical tool used for identifying and quantifying cellular characteristics on a cell-by-cell basis up to tens of thousands of cells per second. This technology is used in research and clinical studies with various biomedical and therapeutic applications such as investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. Flow cytometry has many advantages over traditional microscopy since it enables the analysis of a greater number of cells in a fraction of the time. At Cytek, we are focused on accelerating the adoption of flow cytometry for one simple reason: to fuel scientific discovery. We have leveraged our highly experienced, best-in-the-business team to bring forth an innovative new class of flow cytometry solutions. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before. As a company, we also seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe. For more information, visit www.cytekbio.com.

CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients. Our CoalesceNT™ platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.

Cytologics specializes in customized procurement of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The Company’s supplier network of FDA-registered, GMP-compliant blood collection centers ensures fresh donor material is available to customers from the Cytologics isolation laboratory. Human biological material, including peripheral blood, is isolated into various primary cell types and proteins for fresh and frozen distribution to life science customers. We make it easy to find the right cells to advance your research. All products are well-characterized, tested for blood borne pathogens and guaranteed for cell viability and purity. We also offer a wide range of research services to support your basic and translational research activities.

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale

Dalton Bioanalytics is developing new analytical technology to unlock access to the wealth of information available in blood in pursuit of greater human health. Dalton has plans to resolve the inefficiency and expense that plagues traditional laboratory testing by digitizing the biochemical composition of blood and translating that digital signature into a comprehensive array of actionable health insights. The company is named after John Dalton—the father of modern atomic theory and eponym of the atomic mass unit—in recognition of mass spectrometry, its core enabling technology.

Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene®, which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month, without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology. Daré’s EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Daré is developing a topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra®, for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer.

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

The BIOVIA portfolio integrates the diversity of science, experimental processes and information requirements, end-to-end, across research, development, QA/QC and manufacturing. Capabilities include Scientific Informatics, Molecular Modeling/Simulation, Data Science, Laboratory Informatics, Formulation Design, BioPharma Quality & Compliance and Manufacturing Analytics.Subsidiaries: Accelrys Ltd, Synomics Ltd, VelQuest Corporation, others.

Datavant makes the world's health data secure, accessible, and usable. Datavant is a data platform company for healthcare. We drive data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Through proprietary technology, the world's most robust healthcare network, and value-added services we protect, connect, and deliver the world's health data. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners. To learn more about Datavant, visit datavant.com.

Daybreak Labs is a startup support company that helps startups shorten the time from invention to market by providing a unique combination of expertise, facilities, and equipment.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

DC3 Therapeutics is a full service Contract Research Organization (CRO). We offer a full set of services necessary for drug discovery, pre-clinical and IND enabling studies. Our services include histology and in vitro pharmacology as well as molecular, cellular, and micro-biology. We are happy to work with our clients to custom tailor experiments according to their research and development goals. Because we understand that drug development is a fast paced and demanding environment, we guarantee that our services are performed accurately. And to ensure a quick turn-around time, each customer is assigned a secured DC3 account to conveniently download data, schedule pickup, and submit inquiries. Our team, who are committed to superior customer service, has extensive experience in the drug development process and the pharmaceutical industry. You can rely on us to deliver quality data.

Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance.

DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide strategic insights that accelerate innovation in precision medicine. Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products. DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), oncology biomarkers, liquid biopsy, NGS, spatial biology, omics market segmentation (Market Reports), the entire life sciences industry (BioTrack), and more. Internal teams such as the Culture Committee, Women* in Consulting, and Queers in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine. DeciBio Consulting, LLC recently launched DeciBio Ventures. This venture capital and creation firm invests in and supports ground-breaking companies in the precision medicine space.

Deep 6 AI is a clinical trials software company based in Pasadena, California, founded in 2016. The company focuses on accelerating patient recruitment and enhancing clinical research through AI-powered analysis of real-world clinical data. In March 2025, Deep 6 AI was acquired by Tempus, further integrating its capabilities into Tempus' healthcare ecosystem. The company specializes in AI-powered patient matching, which analyzes both structured and unstructured electronic medical record data to identify eligible patients for clinical trials. Its platform connects healthcare organizations, researchers, and life sciences companies, streamlining trial workflows. Deep 6 AI also generates real-world evidence to support rapid clinical trial feasibility analysis and data-driven protocol design, utilizing natural language processing and machine learning to process data from over 25 major healthcare organizations.

Deep Apple Therapeutics is writing a new playbook for drug discovery, leveraging a powerful combination of cryo-EM enabled structural biology, AI-powered pocket extraction, and more. The company is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders.

Our mission is to improve the way we grow cells for stem cell R&D and cultured meat production. We care about making a positive impact in reducing animal dependency for lab reagents and eventually for food as well. Defined Bio's journey starts with transforming stem cell growth medium by understanding the most critical stem cell research needs - cell growth quality, cost, and ease of use. To meet the growing demands of various customer segments, we realized that we would have to optimize all of the fundamental ingredients of defined, animal free growth media: growth factors, proteins, buffers, and growth/differentiation analysis. We have developed innovative reagents across traditional recipes, leveraging published and optimized recipes from leaders in the field. The result is exceptional reagents, media, and protocols that will materially improve quality and reduce the cost of growing stem cells and iPSC derived cells.

Applying novel, high throughput screening technologies to deliver therapeutics that address the most difficult problems in clinical medicine

DelNova, Inc. is an innovative drug development company targeting unmet medical needs, including complications arising from the use of botulinum toxin (e.g., Botox®, Dysport®, Xeomin®, Jeuveau®). Our first product under development, ReViVox™ (U.S. patent allowed), is based on a clinically validated drug and will address the impacts of unintended localized paralysis from therapeutic and aesthetic botulinum toxin [BoNT] injections. There is currently no reversal agent to safely resolve these side effects; patients can wait weeks or months for drug-induced paralysis to subside. Business Summary: DelNova is developing innovative therapeutics based on an in-depth knowledge of drug delivery. Many unmet patient needs are addressable by modifying the use of known drugs to target delivery for a more efficacious, yet safer outcome. The first product under development is based on a known drug, currently approved for use in other medical conditions and with a different route of administration. The novel formulation will be used for the reversal of undesirable side effects resulting from neurotoxin injections [eg. BOTOX (TM] in both medical and cosmetic uses. Problem: Botox™ (or other BoNT) injections may result in temporary, but undesirable side effects. Transient adverse effects are due to neurotoxin infiltrating into nearby tissue, causing unintended localized paralysis. This could be attributed to either poor injection technique and/or toxin spread. There is no reversal agent to safely mitigate unintended adverse effects; the only option is to wait until the effect of the drug paralysis subsides (weeks to months). For cosmetic procedures, side effects may include droopy eyes or brows, arched eyebrows, or misalignment . In some medical procedures adverse effects may include weakened neck muscles (for migraine ) or difficulty urinating ( for overactive bladder) . Solution: ReViVox(TM); a reversal / rescue product for muscle recovery post BoNT treatment.

Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif.

Denovo Biopharma is a private San Diego based biotech company, also operating in China, providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effects. By identifying biomarkers correlated to patients'​ responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in targeted patient population to achieve higher efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in most therapeutic areas, such as oncology and neurological diseases.

De Novo Software is the premiere provider of Flow Cytometry Data Analysis Solutions. Whether you are analyzing a few dozen samples a day in the lab, or hundreds of samples a day in a high-throughput setting, we have a specialized solution just for you. Our standalone software package, FCS Express, is full of features for novice and sophisticated users alike. Plus, we have a long history of providing custom solutions to clients with unique data analysis needs.

DERMALA, Inc. is a pioneering consumer dermatology startup leveraging the power of the human microbiome and cutting-edge data analytics to develop innovative, patented, science-backed, and clinically validated solutions for a range of skin conditions including acne, eczema, and skin health & longevity.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company’s lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.

Dermavant Sciences, an Organon company, is a biotechnology firm focused on immuno-dermatology. The company specializes in developing innovative therapies for chronic skin conditions, particularly plaque psoriasis and atopic dermatitis. Acquired by Organon in October 2024, Dermavant aims to address unmet medical needs in dermatology through efficient research and clinical development. Dermavant's flagship product is VTAMA® (tapinarof) cream, which is FDA-approved for treating mild to severe plaque psoriasis in adults. The company is also advancing its pipeline with promising results in atopic dermatitis and developing DMVT-506, a next-generation treatment for inflammatory diseases. With a commitment to patient-centric innovation, Dermavant seeks to redefine standards of care in dermatology through scientifically validated therapies. The company operates with a team of 201–500 employees, primarily based in California, and utilizes advanced tools for data analytics and clinical research.

It all started 40 years ago, when we dedicated ourselves to finding scientific solutions using components from natural sources such as Quillaja and Yucca. Since then, Desert King has been leading the way in responsibly sourcing and reliably delivering saponin based products to the world. We are a company based in the United States, Chile, and Mexico. From these locations, we supply products to more than 1,000 customers worldwide, all of whom endorse the quality of our products. We maintain long-term relationships of trust with our customers, reaching more than 60 countries. Our high value-added products provide solutions to global needs in a variety of industries, such as health, human and animal nutrition, cosmetics, mining and agriculture. This includes our QS-21, which is globally accepted as the human vaccine adjuvant quality benchmark. As pioneers in Quillaja domestication with more than 15 years of experience, we have established plantations to meet the growing worldwide demand while safeguarding the integrity of the native forest. Additionally, Desert King actively contributes to the protection and recovery of Quillaja Saponaria forests through sustainable development and harvesting techniques.

Polaris Pharmaceuticals, is a biopharmaceutical development and manufacturing organization (CDMO) specializing in biologics derived from microbial systems. We have manufactured clinical material for trials in the United States, Europe, China, Taiwan, Australia, and Korea. Polaris Pharma offers a comprehensive range of process and analytical development and high-quality cGMP pre-clinical and clinical manufacturing services. We offer services for the following: • Process Development • Master and Working Cell Bank Propagation • Pre-Clinical/Clinical Manufacturing • QC Method Development • In Process Testing • Release Testing • Stability Storage and Testing • Availability to provide high purity WFI and PW • Custom Buffer and Media Manufacturing • Contract Filling, Labeling, Inspection • Microbial Based Fermentation Products

We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.

Desktop Health develops, manufactures, and markets a suite of leading 3D printing and biofabrication solutions. One of products that the company is investigating are 3D printed eardrums.

Dexcom Corporation is a pioneer and global leader in continuous glucose monitoring (CGM). Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started. We are broadening our vision beyond diabetes to empower people to take control of health. That means personalized, actionable insights aimed at solving important health challenges. To continue what we've started: Improving human health. We are driven by over 10,000 ambitious, passionate people worldwide who are willing to fight like warriors to earn the trust of our customers by listening, serving with integrity, thinking big, and being dependable. We've already changed millions of lives and we're ready to change millions more. Our future ambition is to become a leading consumer health technology company while continuing to develop solutions for serious health conditions. We'll get there by constantly reinventing unique biosensing-technology experiences. Though we've come a long way from our small company days, our dreams are bigger than ever. The opportunity to improve health on a global scale stands before us.

Mission Diablo Clinical Research is committed to advancing health through medical research and community service. History Diablo Clinical Research, established by Dr. Weinstein in 1995, has conducted over 600 studies with thousands of patients. Today our database is comprised of over 12,000 patients who have either completed a study with us, are currently enrolled in a study, or have expressed interest in future clinical study participation. Our Founder and Medical Director Richard L. Weinstein, MD a board certified endocrinologist and internist has practiced medicine in the San Francisco Bay Area for 30 years. In 2005 Leonard Chuck, PhD, MD and a practicing internist in our local community for over 20 years joined Diablo Clinical Research as an Investigator. In 2007 Mark Christiansen, MD, who practiced and conducted research in the community for over 17 years, also joined Diablo Clinical Research as an Investigator. Both Dr. Chuck and Dr. Christiansen became Co-Medical Directors of our facility in 2008. Diablo Clinical Research specializes in clinical research. We have been working in our Walnut Creek location for over 17 years. We have 6 MDs on staff with specialties in endocrinology, internal medicine, cardiology, and neurology.

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.

Diagnostic BioSystems is a leading developer of specialty Immunohistochemistry reagents. The company is dedicated to high quality antibody production and development of novel multiplex staining reagents. Building on its strong global presence, Diagnostic BioSystems produces novel, clinically relevant tools for pathology market including: monoclonal and polyclonal antibodies, a wide range of detection systems and ancillary reagents for high quality immunostaining. Custom Monoclonal and Polyclonal Antibody Production Services include peptide synthesis, in vitro and in vivo antibody production, purification and conjugation. Diagnostic BioSystems is an FDA registered medical device manufacturer, operating under FDA 21CFR Part 820 Quality System Regulations and certified under ISO 9001:2008 Quality Management System International standards, manufacturing CE marked medical devices, for use in the European market.

Diality, Inc. is a privately held medical device company based in Irvine, California, focused on improving the lives of individuals affected by kidney disease. The company is dedicated to transforming the dialysis landscape by promoting personalized and cost-effective care models, moving away from traditional centralized facilities. Diality is developing the Moda-flx, a versatile hemodialysis system designed to be simple, mobile, and intelligent. This system allows healthcare professionals to provide personalized dialysis treatments in various settings while maintaining high-quality care. The Moda-flx is user-friendly, reducing training time for clinicians, and features secure data storage and cloud accessibility to support data-driven decision-making. The company is a member of the Advanced Medical Technology Association (AdvaMed) and adheres to its Code of Ethics. Diality has also joined Kidney Care Partners and secured significant investments, including a $24 million Series B2 funding round, highlighting its commitment to innovation in kidney care.

Diazyme uses its proprietary enzyme technologies to develop diagnostic reagents which can be used on most automated chemistry analyzers in user-friendly formats. Diazyme's products include test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, diabetes, and electrolytes.Diazyme DZ-LITE SARS-CoV-2 IgG, IgM CLIA Kits

At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with chronic diseases. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is entering a Phase 1 clinical study soon. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline. Located in South San Francisco, we've built a team of experienced industry professionals dedicated to innovation in immunology drug development.

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

DIMERx is a clinical-stage biopharmaceutical company pioneering a proprietary dimer technology platform to develop novel chemical entities for high-impact, underserved medical conditions. Co-founded by Gregory Beyer, Harvinder Dhani, and Nikhilesh Singh, PhD, the company also collaborates closely on clinical strategy with Maurizio Fava, MD, Chair, Mass General Brigham Academic Medical Centers Psychiatry Department. The company’s lead asset, DMX-101, is a covalently modified, chemically stable, halogen-free buprenorphine dimer (CAS No: 1820753-68-1) that acts peripherally at the source to provide non-addictive pain relief. DMX-101 is in phase 2 clinical development for chronic lower back pain. Across Phase 1 and Phase 2a studies involving over 400 human subjects and patients, it has demonstrated a favorable safety profile—including pancreatic safety—and clear analgesic benefits. DIMERx’s second program, DMX-201, is a covalently linked dimer of arginine and agmatine—a next-generation nitric oxide (NO) donor being developed for conditions involving endothelial dysfunction, such as vaso-occlusive crisis (VOC) pain in sickle cell disease, where treatment options remain dominated by centrally acting opioids.

Direct Electron designs, manufactures, and delivers next-generation direct detection cameras for electron microscopy. Our vision—Innovation Propelling Discovery—is focused on empowering our customers to efficiently and continually expand the frontiers of science. Our approach involves: (1) A strong commitment to research and development that enables us to continually offer new technological innovations, (2) Unique features to improve efficiency in data collection and processing, and (3) A collaborative culture with exceptional customer service and support.

We are a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows.  Powered by a culture of continuous improvement, extraordinary talent and innovation, we ‘create better together' by partnering with healthcare professionals. Our extensive range of products, services and integrated technologies fuel active lifestyles. 

DNA COMPASS is implementing ‘last mile' bioinformatic solutions which bridge the gap between centers of genomic discovery and community health practices. Bringing to market data analytics and collaboration solutions which support healthcare professionals by extending the reach of data-driven medicine into community practices. WHY: At DNA Compass, we believe linked health data must work harder, faster, and for more patients. It must empower clinicians NOW to accelerate accurate diagnoses, increase treatment success, and deliver better outcomes. BREAST CANCER DEMO http://dnabreast.com

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

DNA Link Sequencing Lab is a business unit with DNA Link, Inc, which is dedicated to providing DNA sequencing services to researchers worldwide. Founded in 2000, it has extensive experience in all genomics tools, and our fleet of sequencers include PacBio Sequel, RSII, HiSeq and NextSeq as well as Affymetrix array platforms.

DNARx is a company developing multiple therapeutics for major unmet medical needs, with demonstrated vaccine capabilities as well as protein expression. The company has been awarded a DARPA contract for up to $10.7 million to develop medical countermeasures against biological threats.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

DotLab measuresdisease-specific biomarkers and appliesadvanced biostatisticsfor non-invasiveendometriosis​ testing. ​​​​​​

Dovetail Genomics is reimagining the life sciences by unlocking access to genomic structure at an unparalleled level. Through Dovetail Genomics' proprietary proximity ligation technologies, the 3-D architecture of the genome is captured alongside primary sequence information using standard next-generation sequencing (NGS) approaches. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing and microbiome analysis in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more. Through our services and assay kit offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, and haplotype phasing in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more. Through our services and assay kit offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level.

Drake Integrations is an experienced control systems and commissioning consulting firm providing comprehensive expertise in the design and implementation of HVAC, building automation and energy management systems. We offer commissioning, engineering and quality control services for a variety of clients including commercial, military, luxury residential, retail, higher education, K-12 schools, bio-tech, data centers, hospitality and healthcare.

At Drawbridge, we’ve created the OneDraw™ technology to transform the way blood is sampled and shipped. But that’s just the start. Our ultimate goal? To give everyone, everywhere access to the powerful health information within their own bodies.

Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.

The Nations Leading Beverage Development Firm⁣. Drink Labs was founded to help entrepreneurs develop their beverage ideas quickly. Our experience in the industry has allowed us to create a process that takes you from concept to shelf. Our in-house lab is located in the Los Angeles, CA. We excel in innovation + provide our clients with the support & attention needed to launch a successful beverage brand. Developing a beverage is tough, but we are here to make it easier for you. At Drink Labs, we believe in teamwork, & our ultimate goal is to work collaboratively with you to turn your dream into a reality. We source pure, high-quality ingredients & develop brands that promote health + wellness. We aim to create beverages that are both delicious & nourishing for your customers.

Dualitas Therapeutics is a biotechnology company pioneering the future of bispecific antibody therapies for immune and inflammatory (I&I) diseases and beyond. Powered by our proprietary DualScreen™ discovery engine and a growing library of novel cell surface proximity engagers, our pipeline—including lead programs DTX-103 and DTX-102—has demonstrated compelling preclinical evidence supporting its potential to address important unmet patient needs. We offer partnering opportunities on the next generation of bispecific therapies in I&I diseases – and beyond.

Duet BioTherapeutics is an immunotherapy company creating a new category of bispecific oligonucleotide treatments designed to target dormant immune cells within the tumor microenvironment. Activation of these antigen-presenting cells removes the immunosuppressive shield around the tumor and jump-starts T cell-mediated immune responses to kill cancer cells.

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcoholic hepatitis (AH), COVID-19 patients with acute liver or kidney injury, and nonalcoholic steatohepatitis (NASH).

DxTerity is bringing the power of precision medicine to autoimmune disease. We are pioneering the use of RNA-based immune system profiling to better understand the root causes of immune mediated conditions. Our goal is to provide more personalized care for autoimmune sufferers and empower patients with more detailed information about their condition so they can better navigate their complex health journey.

Medical device sales/distribution organizations needed for a non-narcotic chronic pain treatment solution develop by DyAnsys Inc. Be a part of a billion-dollar market. This innovative solution has tremendous growth potential with the current focus on reducing the use of narcotics for pain treatment. DyAnsys Inc. has been growing rapidly and needs to expand its coverage of the U.S. market. Distributors who are already working in the pain management field and have a base of pain management clients are preferred. Successful candidates should: • Have been in the medical device sales and distribution business for at least five years. • Have a sales force or access to 1099 reps to assure full territory coverage. • Be able to focus on DyAnsys products to grow the business rapidly. To learn more: Call 1-888-950-4321 or e-mail new.distributor@dyansys.com DyAnsys Inc. is a global company, headquartered in the Silicon Valley (California, USA), and is led by a worldwide team of professionals drawn from the medical, mathematical and IT fields who are working hard to make DyAnsys a worldwide leader in providing advanced medical diagnostic and monitoring systems to clinicians in individual practices and hospitals. By using sophisticated mathematical analysis of the ECG and other electrical signals, DyAnsys applications focus on chronic and acute pain, anesthesia, diabetes, and fetal heart monitoring.

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines.

DynoSense Corp. is a medical technology founded by successful high tech veteran, with a mission to “innovate best in class products and services for better, longer, and healthy life that are integrated, accurate, secure, elegant, and simple to use”. We call it “Innovation For Life”.

At Dyve Biosciences, we leverage our proprietary transdermal platform to deliver intuitive, targeted pH modulation to treat a range of immunologic and oncologic diseases. By directly targeting the acidic microenvironments that drive cancer cell growth and inflammation, we are taking decades of proven science from the petri dish to the patient.

Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.

In 1982, the visionaries at Earthrise® created the first spirulina farm in the sun drenched California desert. Today, we continue to produce the worlds best spirulina in our fully sustainable GMP approved California facility. Go green with Earthrise. Spirulina, a tiny aquatic plant has been eaten by humans since prehistoric times and is grown worldwide as a healthy food. Imagine a vegetable with more protein than soy, more Vitamin A than carrots, more iron than beef, profound source of protective phytochemicals, naturally low in fat, source of the essential fatty a...cid GLA and is easy to digest. Learn more about the unique blue Bilin protein of Spirulina.

Eat Just is a food technology company with a mission to build a healthier, safer and more sustainable food system in our lifetimes. The company’s expertise, from functionalizing plant proteins to culturing animal cells, is powered by a world-class team of scientists and chefs spanning more than a dozen research disciplines. Eat Just created America’s fastest-growing egg brand, which is made entirely of plants, and the world’s first-to-market meat made from animal cells instead of slaughtered livestock.

Analytical Testing & Consulting

EchoPixel is building a new world of patient care with its interactive, 3D medical visualization software. The True 3D system allows medical professionals to interact with patient-specific organs and tissue in an open 3D space emanating from a display, enabling doctors to immediately identify, evaluate, and dissect clinically significant structures. In diagnostic, surgical planning and image guided treatment applications, EchoPixel is a privately held, venture backed company located in Santa Clara, CA.

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.

Eclipse Foods makes plant-based dairy products that are indistinguishable in flavor, texture, and functionality from conventional dairy. Eclipse's patent-pending dairy platform recreates micelles (the magic of dairy milk) from plants to create 100% plant-based and non-GMO dairy products that win over mainstream consumers. Our products are made without soy, nuts, coconut, gluten, GMO's, gums or stabilizers, making them free from all common allergens and much cleaner than other products. We are the team behind JUST Mayo, have chef'd/ staged at 16 Michelin stars, and are alt-protein experts. We've raised over $60M from leading investors such as Y Combinator, the chairman of Beyond Meat, the founder of Reddit, the creator of Gmail, a former Dreyer's exec, various top-tier VCs, and more. OUR MISSION: to create a more sustainable, healthy, and humane food system by making amazing plant-based foods that require no sacrifice.

Family owned and operated since 1967, Earth Friendly Products makes ECOS plant-powered laundry detergents and cleaners that are safer for people, pets, and the planet. ECOS cleaners are made in the USA using global ingredients, without dyes, formaldehyde, 1,4-dioxane, parabens, phthalates, or optical brighteners. ECOS has won many awards for its green chemistry innovations, including the U.S. EPA 2021 Safer Choice Partner of the Year award. Earth Friendly Products/ECOS is a WBENC-certified Women-Owned Business Enterprise and an NMSDC-certified Minority Business Enterprise. ECOS, Baby ECOS, ECOS Pets, and ECOS PRO cleaners are available at major club and grocery retailers and natural foods stores throughout the U.S., internationally, and online. For more information and retail locations, visit ecos.com.

Edan is a healthcare company dedicated to improving the human condition around the world by delivering value-driven, innovative and high-quality medical products and services. For over 20 years, Edan has been pioneering a comprehensive line of medical solutions that address a broad range of healthcare practices including Diagnostic ECG, OB/GYN, Ultrasound Imaging, In-Vitro Diagnostics, Patient Monitoring, Point-of-Care Testing, and Veterinary. Healthcare professionals around the world depend on Edan's breakthrough medical technologies and outstanding customer support. Till now, EDAN has reached over 170 countries and areas and 40,000 medical facilities with Industry Leading Healthcare solutions.

亿腾医药从2001年成立以来，始终以链接全球优质药品与病患，成为中国领先的专利及品牌药物供应商为愿景与使命。一方面我们“传承经典”，持续收购全球跨国药厂著名的经典品牌产品，通过与有效的运营成本管控和中低端医疗机构拓展，使更多中国病患从品牌及专利药物中受益。另一方面我们不断“开拓创新”，持续引进海外研发机构的专利药物，参与国际多中心临床试验，力争在中国与国际同步上市新药，为临床医生提供更多对疾病的治疗手段。多年来我们快速拓展业务，在多领域进行战略部署，目前正在逐步从引进研发营销型组织升级成为全产业链组织。 我们已在全国30个省拥有近1,000名专业学术推广人员，覆盖了19,000多家医院和超过20,000家药房。多年来，我们和跨国医药企业、专业医药公司、领先研发机构合作，通过授权引进专利药物、成立合资公司、资产并购、建立战略联盟、独家经销等形式，不断丰富包括抗感染治疗、抗肿瘤治疗、呼吸系统疾病治疗、心血管疾病治疗、肾科疾病治疗在内的多领域药物产品组合。 此外，我们在研的几款新药也可望于近期上市。其中具有变革意义的VASCEPA®（二十碳五烯酸乙酯，原名AMR101）胶囊，已被证明可明显降低相关患者群体的甘油三酯水平而不升高LDL-C水平，其降低多种心血管疾病风险的试验结果也先后发表于2018年11月的《新英格兰医学杂志》和2019年3月的《美国心脏病学院杂志》。近期， 美国FDA又正式接受了VASCEPA®胶囊用于降低心血管风险补充新药申请（sNDA），并同时授予了优先审评资格。亿腾自2015年获得VASCEPA®中国大陆以及港澳台地区的开发、商业化及供应等活动，包括这项关键性注册临床研究的管理和资助。我们已经在中国完成了一项药代动力学（PK）研究以及一项中美健康受试者PK特征的种族差异比较研究；目前正在开展一项III期临床试验。 “专业、卓越、责任、执着”是亿腾的价值观。我们的职业和生命与健康相关，专业是最基本准则，精益求精的原则贯穿于我们工作的每一个细节，尽忠职守是我们对于每一项任务的基本态度，面对信念和使命，我们百折不挠永不放弃。为了让中国患者使用到全球最优质的药品和领先的医疗技术，我们砥砺前行。

Edeniq, Inc. is a leading biotechnology company specializing in innovative, analytical solutions for the biofuels industry. With a focus on the analysis of fiber and cellulosic ethanol, Edeniq helps its customers quantify and qualify increased yield value and reduced carbon intensity, and optimize plant operations. Founded in 2008, Edeniq’s experienced team and strong customer focus have established the company as the top analytical testing service provider for ethanol producers across North America. Learn more at www.edeniq.com.

Edico Genome is a biotechnology company that specializes in developing cutting edge solutions for genomic sequencing analysis to provide unprecedented speed, scale, and accuracy.

The company works with doctors to develop medical devices related tostructural heart disease and critical care monitoring.

EicOsis is a small start-up company located in Davis, CA focused on developing non-opioid treatments for pain in humans and animals.

At Eidogen-Sertanty, we vigorously pursue our mission to help scientists discover new medicines through innovative software technology and knowledgebases. Eidogen-Sertanty is a privately held company providing knowledge-based discovery solutions to biotechnology and pharmaceutical organizations through software, content, and collaborative service arrangements. Since 2003, we have been licensing our software and database products to top pharmaceutical and biopharmaceutical companies all over the world. Through our product and service offerings, Eidogen-Sertanty proudly helps companies worldwide make advances in numerous disease areas including cancer, AIDS, arthritis, general infection, and pain.

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in San Rafael, California International Offices: Ekso Bionics Europe GmbH Friesenweg 20 Hamburg, 22763 Germany Tel: +49 40 800 4049 20

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity's greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

Element Biosciences is a multi-disciplinary startup focused on developinggenetic analysis tools for the research and diagnostic markets.

Elevai Labs is a California-based medical aesthetic company that develops science-driven topical skincare technologies for the medical dispensing market.

Eliaz Therapeutics (ETI) was founded in 2015 by Isaac Eliaz, MD to leverage his significant expertise in Galectin-3 and Apheresis to develop and commercialize a therapeutic Apheresis device that removes Galectin-3 from the blood. Galectin-3 has a causal role in many life-threatening inflammatory and fibrotic diseases, immune dysregulation (including the cytokine storm), kidney deterioration and cancer that do not have effective treatments today. The initial indication will be Sepsis and Sepsis induced Acute Kidney Injury (AKI). AKI is a sudden decrease in kidney function with or without kidney damage, occurring over a few hours or days. Annual US hospitalizations for AKI are in excess of 4,000,000 and deaths exceed 500,000. Diabetes, hypertension, and advanced age are primary risk factors for sepsis and acute kidney injury. It is increasingly recognized as an in-hospital complication of sepsis, heart conditions, surgery and Covid-19. Its most severe stage requires treatment with dialysis or renal transplant therapy. Acute kidney injury is also associated with higher likelihood of long-term care, incidence of chronic kidney disease and hospital mortality, and higher long-term health care costs. Currently, there are no approved treatments to prevent, interrupt, or hasten recovery from sepsis and sepsis-AKI. XGAL3 apheresis has the potential to do all three and thus exert a dramatic impact on sepsis patient management and outcomes, potentially saving hundreds of thousands of lives per year.

Elim Biopharmaceuticals, Inc. is a leading life science service company for the biotech, pharmaceutical, and medical communities, offering a range of services from sequencing to synthesis, including drug quantification.

Elixir Medical is committed to transforming care of patients with heart and vascular disease through innovation. Since 2005, the company has continually sought to improve the treatment of vascular disease with: - Drug-eluting coronary stent systems (DES) - Fully resorbable drug-eluting scaffold systems (BRS) - Drug-eluting coronary bioadaptor systems Its latest innovation — the DynamX™ Coronary Bioadaptor System — is designed to be a significant advancement beyond drug-eluting stents (DES). Elixir Medical’s innovations are designed to make a meaningful change in patients’ lives. The company does not simply want to engineer a better medical device. Saving lives and helping patients enjoy their daily life is what drives us every day.

Elpida Therapeutics is a biopharmaceutical company that focuses on developing treatments for rare diseases, offering hope to children and families affected.

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.